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1 INTRODUCTION 
1.1 Alzheimer’s disease 
In the year 1907, two scientists (Alois Alzheimer and Oskar Fischer) (Figure 1) 
simultaneously described the presence of plaques and tangles in the brains of elderly 
people. Alzheimer published a short report about senile plaques observed in his patient 
Auguste Deter’s post-mortem brain (Alzheimer, 1907). Fischer published a clinico-
pathological study of 16 cases of senile dementia describing the neuritic plaques 
(Fischer, 1907). Later, in the year 1910, the disease was named after the Bavarian 
psychiatrist as ‘Alzheimer’s disease’ (AD) by his colleague and co-founder of AD, 
Emil Kraepelin (Graeber et al., 1997).  
 
Figure 1 Alois Alzheimer (left) and Oskar Fischer (right) 
Figures reproduced with permission from Oxford Journals. 
 
AD is the most common neurodegenerative disorder, diagnosed in people over 65 
years of age (Brookmeyer et al., 1998), estimated to affect 35 million people 
worldwide and may quadruple by 2050, reports approximate every 69 seconds 
someone develops AD (Alzheimer'sAssociation, 2010; Brookmeyer et al., 2007). 
Early clinical symptoms of the disease are imperceptible and start with minor lapses in 
episodic memory. Later it develops into dementia and disorientation associated with a 
lack of interest in hobbies, word-finding difficulties, spatial disorientation, trouble 
with math, stereotyped manual tasks, disturbance of balance and other impairments 
(mild cognitive impairment). Disease severity progresses to global cognitive deficits, 
full disorientation, and profound memory impairment. In the last state, the patient is 
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commonly bed-ridden and dependent on permanent care. Self-portraits of an artist by 
name William Utermohlen depicts deleterious effect of the disease on him (Figure 2) 
 
Figure 2 Self-portrayals by William Utermohlen. An artist who suffered from Alzheimer’s disease 
painted a series of self-portraits during the progression of his illness. He died in 2007 leaving an 
expressive legacy, his paintings during his sufferings showed his descent into dementia. (Courtesy: 
Galerie Odille Boicos, Paris) 
1.2 Neuropathological phenotype of Alzheimer’s disease 
Albeit the clinical symptoms, confirmation of AD requires post-mortem studies, 
especially the classical microscopic observation of lesions in hippocampal sections 
and the association cortices of the frontal, temporal and parietal lobes. Overall, 
multiple regions of the brain are affected as a result of the disease, including 
hippocampus, neocortex, amygdala, cholinergic system in the forebrain, and the 
monoaminergic systems of the brainstem’s neuronal population (Arnold et al., 1991; 
Braak and Braak, 1991; Hyman et al., 1984; Whitehouse et al., 1982). The Aβ peptide 
was identified and sequenced from the meningeal blood vessels of AD patients in 1984 
(Glenner and Wong, 1984), and the following year it was recognized as the primary 
component of the neuritic plaques in the aforementioned brain areas of AD patients 
(Masters et al., 1985; Scheff et al., 1990; Selkoe et al., 1986). Additionally, neuritic 
plaques are also present in the outer walls of parenchymal arterioles, small arteries, 
capillaries, and venules. Post-mortem studies of the brain suggest that the neuritic 
plaques and neurofibrillary tangles are the two principal neuropathological hallmarks 
of AD. Immunohistochemical studies show a decrease in the synaptic density in the 
frontal cortex of AD brain, suggesting reduction in active synaptogenesis (Scheff et 
al., 1990). Furthermore, loss of synaptic ending precedes the neuronal loss that leads to 
cognitive impairment (DeKosky and Scheff, 1990).  
 
Neuritic plaques are found extracellular, proximally surrounded by activated 
microglia, reactive astrocytes, and dystrophic axons and dendrites (Pike et al., 1994; 
Rozemuller et al., 1986). Along with plaques, there are diffuse or pre-amyloid plaques 
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present in the same brain regions. Their occurrence is detected under light microscope 
in the brain lesions of AD patients and in cognitively normal, late middle-aged and 
elderly healthy individuals (Dickson et al., 1995; Price and Morris, 1999). 
Additionally, diffuse plaques generally lack amyloid fibrils and are not associated with 
dystrophic neurites or altered glia, suggesting these diffuse plaques may predate 
fibrillar neuritic plaques (Dickson, 1997).  
 
Apart from neuritic plaques, the other diagnostic hallmarks of AD are the 
neurofibrillary tangles, visualized by Bielschowsky silver staining. Tangles are non-
membrane bound masses of paired helical filaments (PHF), formed by a 
hyperphosphorylated form of the microtubule-associated protein, tau (Grundke-Iqbal 
et al., 1986). 
 
Alternatively, Khachaturian proposed another hypothesis stating that disturbances in 
calcium homeostasis are a cause of neurodegeneration in AD (Khachaturian, 1994). 
Initially, this hypothesis was promulgated due to lack of enough supportive 
experimental evidence, while later reports backed the hypothesis (Mattson et al., 
2000). 
 
With respect to the neurotransmitter phenotype, degeneration of cholinergic neurons in 
the nucleus basalis of Meynert is responsible for cognitive impairment in AD (Davies 
and Maloney, 1976). Remarkable reduction of choline acetyltransferase (CAT) and 
glutamic acid decarboxylase activities (acetyl choline synthesizing enzymes) are found 
in AD brains (Perry et al., 1977). Davis along with other scientists further reported the 
involvement of GABAergic transmission in AD (Davies et al., 1998). In addition to 
the involvement of cholineric and GABAeric neurons, neurons using glutamate, 
somatostatin, corticotrophin releasing factor and serotonin also undergo degeneration 
in AD brains (Bennett et al., 1997; Moller, 1999). Due to the complexity and multiple 
neurotransmitter deficits involved in AD, apart from the treatment of cholinergic 
deficiency, no other factors seems to lead to serious therapeutic implications (Selkoe 
and Schenk, 2003).  
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1.3 Genetics of Alzheimer’s disease 
Advancements in molecular genetics have led to a better understanding of AD beyond 
the prominent age factor in sporadic forms. Mutations in at least one of three genes, 
encoding Presenilin 1, Presenilin 2 or APP, have been identified in familial AD 
(FAD), where cerebral levels of Aβ are elevated (Bertram and Tanzi, 2008). 
Numerous studies have been conducted to identify genetic links to the susceptibility of 
AD, since all the previously reported links (APP, PS1 and PS2) were related to rarely 
found early-onset AD. In the year 2002, Fagan and colleagues correlated 
Apolipoprotein E (ApoE) and Aβ to late onset Alzheimer’s disease with some strong 
evidence (Fagan et al., 2002). ApoE is a plasma protein involved in the transportation 
of cholesterol and other lipids. There are three isoforms of ApoE (ApoE II, ApoE III 
and ApoE IV) found among humans. The ApoE4 isoform was reported to be involved 
in the development of late-onset AD. ApoE 4 is the only genetic risk factor for late 
onset AD (Bertram and Tanzi, 2008). Decreased clearance of the extracellular Aβ due 
to impaired function of neprylisin or insulin degrading enzyme (IDE) (Qiu et al., 
1998), which is an Aβ degrading protease, is speculated to be the reason for the 
pathogenesis. Additionally, due to an increased β-secretase expression in the brain, 
and thereby increased cleavage by β-secretase, there will be an increase in Aβ 
production. 
1.4 Cell and molecular biology of Alzheimer’s disease 
1.4.1 Amyloid precursor protein 
The Amyloid precursor protein (APP) is a member of a family of evolutionarily 
conserved type I transmembrane glycoproteins. The APP gene is located on 
chromosome 21 (Goldgaber et al., 1987; Kang et al., 1987; Ponte et al., 1988; Robakis 
et al., 1987; Tanzi et al., 1987; Tanzi et al., 1988). APP occurs in three major isoforms, 
APP695, APP751, and APP770. Their molecular weight ranges between 110-140 kDa, 
depending on alternative splicing. Of these, APP695 is predominantly expressed in 
neurons, while the other two variants are expressed in neuronal and non-neuronal cells 
(Sisodia et al., 1993). APP751 and APP770 lack a 57-residue domain homologous to 
Kunitz serine protease inhibitors family (LeBlanc et al., 1991).  
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1.4.2 APP processing and secretase activities 
Newly synthesized transmembrane APP is translocated into the endoplasmic reticulum 
(ER) and post-translationally modified through the secretory pathway. Post-
translational modifications of APP include phosphorylation, tyrosine-sulphation and 
N- and O-linked glycosylations (Oltersdorf et al., 1990; Weidemann et al., 1989). The 
mature APP undergoes rapid degradation following the transportation via the cell 
surface, through an endocytic or a biosynthetic pathway. Only the immature APP 
carrying N-glycosylations undergoes degradation either in the ER or in the cis-Golgi 
(Cook et al., 1997; De Strooper et al., 1993; Haass et al., 1992; Hartmann et al., 1997; 
Kuentzel et al., 1993; Marambaud et al., 1997; Sambamurti et al., 1992; Shoji et al., 
1992). Aβ peptides are cleavage products of APP, successively cleaved by β and γ 
secretase (aspartyl proteases). Apart from these two secretases, α-secretase cleavage in 
the Aβ domain of APP molecule prevents Aβ production (Esch et al., 1990; Sisodia et 
al., 1990). Thus, depending upon the secretase involved in APP cleavage, the pathway 
is termed either amyloidogenic or non-amyloidogenic. 
 
Figure 3 APP processing. APP processing involves proteolytic cleavage by α  or β  secretase and γ  
secretase. In the non-amyloidogenic pathway, α-secretase cleavage occurs in the middle of Aβ 
sequence and leads to the release of several soluble APP fragments. The amyloidogenic pathway is 
initiated by β-secretase followed by  γ secretase releasing Aβ.  
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In the non-amyloidogenic pathway, α-secretase cleavage occurs within the N-terminal 
domain of APP to release a large ectodomain fragment of soluble APPα (sAPPα, 105-
125 kDa) into the extracellular space and retention of C-terminal fragment (α-CTF or 
C83) in the membrane (Haass et al., 1993). α-secretase cleaves within the Aβ domain 
(Lys16-Leu17 bond) precluding the formation and deposition of intact Aβ peptide 
(Lammich et al., 1999). The secreted sAPPα has neuroprotective and memory 
enhancing effects (Furukawa et al., 1996; Meziane et al., 1998). α-CTF, the membrane 
bound product of α-secretase becomes substrate for γ-secretase cleavage resulting in 
the release of p3 fragment to the extracellular space and AICD (APP intracellular 
domain) into the cytosol (Esch et al., 1990; Haass et al., 1993; Haass et al., 1992). 
 
In the amyloidogenic pathway, β-secretase cleavage occurs in the ectodomain of APP, 
releasing soluble APP-beta fraction (sAPPβ) into the extracellular space and leaving 
C-terminal fragment of 99 amino acids (β-CTF or C-99). Subsequently, γ-secretase 
cleaves the β-CTF to secrete Aβ into extracellular space and the APP intracellular 
domain (AICD) is released into the cytosol. AICD triggers a molecular cascade that is 
believed to be acting as apoptotic signal (Ozaki et al., 2006; Passer et al., 2000). 
 
1.4.3 Secretases 
1.4.3.1 α-secretase  
Alpha secretase is a zinc metalloproteinase and member of the Disintegrin and 
Metalloprotease domain (ADAM) protein family, which are expressed on the cell 
surface and anchored within the cell membrane. Several members of adamalysin 
family proteins like tumor necrosis factor-α convertase (TACE) ADAM17, ADAM10 
and ADAM9 show α-secretase activity (Furukawa et al., 1996; Mattson et al., 1999; 
Meziane et al., 1998).  
1.4.3.2 β-secretase 
β-secretase, also called as β-site APP cleaving enzyme (BACE1) or memapsin-2, is a 
type I trans-membrane protein selectively expressed in neurons and has a role in 
myelin sheath formation (Willem et al., 2006). BACE1 contains two active aspartate 
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protease motifs, which cleaves APP and determines the N-terminal end of Aβ 
(Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). 
1.4.3.3 γ-secretase  
γ-secretase has three cleavage sites releasing three different variants of Aβ peptide 
with variable lengths. γ-secretase cleaves APP following ε (position 49) and ζ-
cleavages Aβ1-38, Aβ1-40 and Aβ1-42 are three major species of Aβ corresponding to the 
different cleavage sites.  
1.4.4 Amyloid hypothesis and Alzheimer’s disease 
In 1838, Mathias Schleiden first coined the term amyloid to describe the amylaceous 
constituent of plants (Kyle, 2001). Amyloid is a long straight unbranched fibril with a 
diameter of ~100 Å. It is made up of parallel protofilaments having a cross β-sheet and 
can be stained using Congo red dye (Bennhold, 1922).  
 
Until 1992, Aβ production was considered as a pathogenic event, but this view point 
was changed after reports showing the presence of Aβ in both CSF and plasma in 
healthy individuals. On the other hand, over-production of Aβ or increased ratio of Aβ 
1-42 to Aβ1-40 was suspected to be the cause in early onset AD (Bentahir et al., 2006; 
Cai et al., 1993; Citron et al., 1992; Kumar-Singh et al., 2006; Rovelet-Lecrux et al., 
2006; Suzuki et al., 1994).  
 
 Meanwhile, the amyloid hypothesis became one of the hot topics in the scientific 
community as well as highly controversial (Marx, 1992). The skepticism was due to 
the inconsistency of Aβ toxicity observed in some laboratories. In the next two years, 
Pike et al and Lorenzo reported that the neurotoxicity of amyloid beta requires a 
specific structure (Lorenzo and Yankner, 1994; Pike et al., 1993).  
1.4.4.1 Evidences for Amyloid cascade hypothesis 
There is mounting evidence supporting the role of Aβ as a causative agent in AD. AD-
like neuropathology is observed in Down’s syndrome (Trisomy of chromosome 21) 
caused by APP over-expression and increased Aβ production (Mann et al., 1984; 
Motte and Williams, 1989; Olson and Shaw, 1969). Supporting this observation, 
reports suggest that the duplication of the APP locus on chromosome 21 leads to early 
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onset of AD or cerebral amyloid angiopathy among some unrelated families (Rovelet-
Lecrux et al., 2006). A mouse model with mutant human APP show increased 
extracellular Aβ accumulation and mimics AD pathology and behavioural changes 
(Ashe, 2005). 
 
Mutations in the APP gene within or around the Aβ region which influence production 
or aggregation rate of Aβ, are found in patients with familial history of early-onset AD 
(Chartier-Harlin et al., 1991; Goate et al., 1991; Levy et al., 1990). Increased Aβ 1-42 to 
Aβ1-40 ratio due to inherited mutations in the presenilin genes cause early and severe 
forms of AD (Bentahir et al., 2006; Kumar-Singh et al., 2006).  
 
Fagan et al showed the ApoE affects the Aβ metabolism, deposition and clearance, 
and facilitates Aβ fibrillogenesis. Holtzman et al demonstrated that the murine apoE 
influences Aβ deposition using ApoE knockout mice (Holtzman et al., 1999). 
Furthermore, in a comparison study, where Aβ plaque burden was analyzed between 
APP transgenic mice with either of three different human ApoE isoforms (II, III or 
IV), it was shown that the ApoE isoform influences Aβ deposition. Transgenic mice 
with ApoE4 were reported to have higher levels of Aβ deposits in the brain when 
compared to the transgenic mice with ApoE2 or ApoE3 (Fagan et al., 2002). 
Additionally, in vitro studies show that the ApoE binding to Aβ induces Aβ fibrillation 
(Strittmatter et al., 1993). In summary, numerous reports have confirmed that the 
ApoE 4 allele is correlating to AD risk factor and ApoE 2 allele appears to be 
protective against AD (Corder et al., 1994; Corder et al., 1993; Mayeux et al., 1993; 
Strittmatter et al., 1993). Recently, it has been shown that ApoE4 impairs clearance of 
Aβ across the blood brain barrier (Deane et al., 2008). 
 
In support of the Amyloid hypothesis, several groups reported that the synthetic form 
of Aβ (with different oligomerization strategies) show neurotoxic effects both in vivo 
and in vitro (Barghorn et al., 2005; Busciglio et al., 1995; Deshpande et al., 2006; 
Hartley et al., 1999; Hoshi et al., 2003; Kayed et al., 2003; Lambert et al., 1998; Pike 
et al., 1991). Injection of the synthetic peptides into either tau over-expressing 
transgenic mice, or into animals with human mutations of APP and tau, triggers tau 
hyperphoshorylation, which leads to tangle formation (Gotz et al., 2001; Lewis et al., 
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2001; Oddo et al., 2003; Santacruz et al., 2005). Reports showing a connection 
between tau and Aβ further strengthened the amyloid cascade hypothesis (Rapoport et 
al., 2002).  
 
In primary neuronal cultures, Aβ peptides have been reported to induce degeneration 
through one or more of the following pathways- apoptotic pathways (Loo et al., 1993); 
by induction of toxic levels of reactive oxygen species (Behl et al., 1994); triggering 
nitric oxide production through a NFκB-dependent mechanism (Hensley et al., 1994); 
activating the complement cascade pathway by binding to C1q (Rogers et al., 1992); 
or Aβ can activate the complement cascade without mediation of immunoglobulins. 
 
Figure 4 Amyloid cascade hypothesis: Accumulation of Aβ1-42 that initiates a sequence of 
pathogenic events that are speculated to lead to AD.  
 
1.4.4.2 Intracellular Aβ  
Soon after the Aβ peptide was reported to be the main component of extracellular 
amyloid plaques, there were some studies claiming the presence of intracellular Aβ. 
Both AD and control groups were reported to have intracellular Aβ (Grundke-Iqbal et 
al., 1986).  
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1.4.4.3 Amyloid beta oligomers but not fibrils are toxic to neurons 
Historically, Aβ fibrils have been considered to be primarily responsible for neuronal 
dysfunction and death, since fibrils were detectable in diseased brains and leading to 
neuronal dysfunction, dystrophy and synaptic loss (Geula et al., 1998; Grace and 
Busciglio, 2003; Pike et al., 1991). Buscigloio et al demonstrated that amyloid fibril 
formation alters the tau phosphorylation, which leads to loss of its microtubule binding 
capacity (Busciglio et al., 1995).  
 
There are contradictory reports with respect to toxicity of amyloid plaques. A few 
reports dismissed the role of amyloid fibrils on AD, due to the lack of correlation 
between the plaques and AD pathogenesis (Dickson et al., 1995; Katzman, 1986; 
Terry et al., 1991). On the other hand some investigators supported the concept of 
amyloid fibrils being toxic (Howlett et al., 1995; Lorenzo and Yankner, 1994).  
 
However, emerging evidence suggests that Aβ has the ability to form a diverse set of 
different assemblies, called oligomers, starting from dimers, trimers, tetramers, 
octamers, dodecamers (Aβ*56), all the way up to protofibrils (Barghorn et al., 2005; 
Kayed et al., 2003; Lesne et al., 2006; Shankar et al., 2008). In contrast to fibrils, these 
oligomeric forms of Aβ are non-fibrillar, water-soluble assemblies of Aβ following 
different aggregation pattern and cause neuronal death through different pathways 
(Walsh et al., 2002).  
1.4.4.4 Aβ  oligomers in human and transgenic mice brain  
Biochemical analyses of AD brain samples indicate that the amount of non-fibrillar Aβ 
is associated with synaptic loss by impairing glutamanergic transmission, blocking 
long-term potentiation (LTP), and dementia (Kamenetz et al., 2003; Snyder et al., 
2005; Walsh et al., 2002). Although, insoluble amyloid aggregates and fibrils are 
present in AD patients’ brain, soluble oligomers of amyloid are reported to play a 
crucial role in AD pathogenesis. In particular, extracellular accumulation of Aβ1−42, 
which is more prone to oligomerize compared to Aβ1−40, affects the synaptic plasticity, 
induces a loss of synaptic dendritic spines, and adds to the severity of cognitive 
impairment (Hsieh et al., 2006; Jarrett et al., 1993; Lue et al., 1999; McLean et al., 
1999; Wang et al., 1999). Despite of assays that could measure soluble Aβ, the 
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aggregation state of Aβ could not be identified (Funato et al., 1999; Morishima-
Kawashima and Ihara, 1998; Stenh et al., 2005).  
 
Samples from frontal cortex and putamen revealed the presence of monomeric, 
dimeric and trimeric species of Aβ (McLean et al., 1999). Human CSF samples and 
brain extracts showed the presence of SDS-stable low molecular weight oligomers but 
no higher oligomers, which are non-covalently associated with dimeric and trimeric 
species of Aβ (Enya et al., 1999; Funato et al., 1999; McLean et al., 1999; Roher et al., 
1996; Vigo-Pelfrey et al., 1993).  
 
In the year 2003, Kayed and colleagues produced a synthetic Aβ peptide mimicking 
spherical structure and produced antibodies, which they reported as being 
“conformation specific” antibodies (Kayed et al., 2003). The authors could show that 
the toxicity exerted by oligomers on human neuroblastoma cells (SH-SY5Y cells) 
could be decreased after the treatment with oligomer specific antibodies.  
 
On the other hand, Lesne and colleagues observed that there is no impairment of 
spatial memory in Tg2576 transgenic APP mice in the presence of monomers, trimers, 
or hexamers of Aβ during the first 6 months. Later, the appearance of SDS-stable 
nonamers and dodecamers directly correlate with the changes in spatial memory 
(Lesne et al., 2006). Intraventricular injection of dodecamer Aβ purified from diseased 
brain affect the spatial memory remarkably. The authors addressed these dodecamers 
as “Aβ*56” which may be considered as representative of Aβ derived diffusible 
ligands (ADDLs) derived from brain. In contrast, Lesne and other two groups pointed 
out the lack of correlation between dodecamers and other forms on memory, and 
synaptic form and function (Dineley et al., 2002; Jacobsen et al., 2006; Lesne et al., 
2006). Recently, Shankar et al showed that dimeric Aβ, isolated directly from AD 
patient brains, can act as potential toxic species, impairing LTP and affecting learned 
memory (Shankar et al., 2008).  
 
1.4.4.5 Synthetic Aβ  protofibrils, ADDLs and globulomers  
Snyder and colleagues first reported the presence of Aβ species apart from fibrils 
using synthetic peptides (Snyder et al., 1994). In the same year, Oda et al showed that 
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Aβ and Clusterin (Apo J) mixtures give rise to small toxic assemblies other than fibrils 
and reported for the first time the toxic effect of synthetic Aβ in vitro (Oda et al., 
1994; Oda et al., 1995).  
1.4.4.5.1 Aβ  Protofibrils 
Pioneering studies from Walsh and Teplow showed two distinct derivatives formed by 
Aβ1-40 and Aβ1-42 called protofibrils. Protofibrils precedes fibril formation and has 
similar structural features (Walsh et al., 1997), whose formation is dependent on pH, 
concentration and ionic strength (Harper et al., 1997). These ‘metastable intermediate’ 
protofibrils form fibrils and can dissociate into low molecular weight species (Harper 
et al., 1999; Walsh et al., 1999). Treating primary neurons with protofibrils 
demonstrated their toxicity, induced excitatory post-synaptic currents, and large 
membrane depolarization effects (Hartley et al., 1999).  
1.4.4.5.2 Aβ-derived diffusible ligands (ADDLs) 
In 1998, Lambert and Klein reported a small globular and diffusible form of Aβ1-42 
called ADDLs that assembled when fibril formation is inhibited by synthetic peptides. 
ADDLs are derivatives of synthetic Aβ which appear before the protofibril formation 
and it is reported that they block LTP and cause neuronal death at very low 
concentrations (Lambert et al., 1998; Wang et al., 2002). Following these reports, 
there is quite a number of publications supporting that ADDL preparations could be 
toxic in both in vitro and in vivo. 
1.4.4.5.3 Globulomer-like ADDLs  
There are several ADDLs like structures available today, of which a few are more 
noteworthy: Kayed et al produced Aβ with unique conformation using gold particles. 
These oligomers may start from tetramer to higher oligomers without fibril formation 
and share the same conformation with other ‘Amyloid-like’ synthetic peptides and 
proteins (Kayed et al., 2003). Lesne and colleagues showed Aβ*56, a dodecamer 
produced under in vivo conditions which could affect memory in transgenic animals. 
In the year 2005, Barghorn et al reported a synthetic peptide forming a stable, 
homogenous globular structure, which they addressed as ‘globular amyloid oligomer – 
globulomer’ that affects memory and LTP in transgenic animals (Barghorn et al., 
2005). 
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1.4.4.5.4 Aβ  oligomers of cellular origin  
Similar to human and mouse brain extracts, SDS-stable low molecular weight 
oligomers have been detected in conditioned cell culture medium by over expressing 
hAPP (Morishima-Kawashima and Ihara, 1998; Podlisny et al., 1995; Townsend et al., 
2006; Walsh et al., 2000). Walsh et al., purified the low molecular weight oligomers 
and showed that these oligomers are not only stable to SDS but also to IDE that 
degrade monomeric Aβ. Further, authors showed cell-derived oligomers inhibit the 
maintenance of hippocampal LTP, decrease synaptic activity, which is in line with 
severely affected AD. This effect did not occur on using either Aβ monomers or any 
larger aggregates (Walsh et al., 2005). These observations were supported by Cleary et 
al showing natural oligomers could disrupt cognitive function (Cleary et al., 2005). 
Furthermore, naturally secreted Aβ trimers were found to be neurotoxic and affects 
some specific forms of hippocampal LTP (Townsend et al., 2006). 
 
1.4.5 Neuroinflammation in AD 
The human brain is not an immunologically isolated organ. Despite the earlier 
dismissals claiming immunological features of AD brain as an artefact, mounting 
evidence support AD as a neuroinflammatory disease (Akiyama et al., 2000). Neurons 
and neurites in the AD brain, insoluble Aβ deposits and NFTs act as stimuli for 
inflammation. Microglial cells, the principal immune cell in the brain, are abundant 
around the plaque deposits exhibiting reactive or activated phenotype in AD brain 
(Wisniewski HM, 1973).  
1.4.5.1 Cytokines 
Neuroinflammation with elevated cytokine levels is one of the pathological features 
found in the AD brain. In AD brains, activated microglial cells and reactive astrocytes 
proximally surround extracellular neuritic plaques (Wisniewski HM, 1973). These 
cells release many neuroinflammatory mediators like pro-inflammatory cytokines 
(Griffin et al., 1989), chemokines, proteases, protease inhibitors, adhesion molecules, 
free radicals, and activate the complement systems. The involvement of inflammatory 
mediators in AD brains was first reported with respect to upregulation of the cytokines 
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interleukin-1 (IL-1) and S100 (Griffin et al., 1989). IL-1 is responsible for initiating 
dystrophic neurite formation in diffuse Aβ deposits (Griffin et al., 1995). IL-6 was 
found to be elevated around senile plaques in the cortical and hippocampus regions of 
AD brains (Bauer et al., 1991; Strauss et al., 1992). Further, the involvement of IL-8, 
tumor necrosis factor-alpha (TNF-alpha) and TGF-β were found in the pathogenesis of 
Alzheimer's disease (Akiyama et al., 2000).  
On the other hand, soluble APP-alpha (sAPPα) has been reported to be 
neuroprotective. A recent review suggests that there is a role of cytokine suppression 
in regulating the α- secretase function (Sastre et al., 2008). 
1.5 Alzheimer’s disease therapy 
Average human life expectancy increased dramatically with scientific/medical 
advancements. Increased number of age-related diseases like AD needs urgent and 
efficient therapeutic strategies to influence the disease progression. Albeit the current 
understanding of AD is still incomplete, there are rational efforts that could bring 
some potential diagnostic tools and therapeutic agents to halt and/or reverse the 
disease progression. Pharmaceutical companies are in a stiff competition to develop 
new therapeutics for AD, but the recent failures in clinical phases forebodes the 
chances of many drug candidates remains murky. 
1.5.1 Drugs to treat Alzheimer’s disease 
Existing medicaments offer symptomatic relief to AD patients either by inhibiting 
neurotransmitters or modulating/blocking potential receptors in the brain (Table 1), 
however, does not help to reverse or halt disease progression. Considering the role of 
Aβ aggregation in AD, Aβ is without dispute, a valid molecular target to treat the 
disease. Two strategic approaches have been intensively implemented, (i) either to 
inhibit the production of Aβ or, (ii) to prevent of aggregation/formation and 
elimination of toxic forms of Aβ from the system. Despite decades of hard-work very 
few drugs targeting either of the two approaches entered the clinical phases. But as of 
now, there are no drugs available in the market with any of those two curative 
approaches. Recently, a gamma secretase inhibitor (Semagacestat) was dropped out of 
the clinical phase III due to adverse effects (Lilly, 2010).  
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Table 1 List of drugs currently used to treat AD 
Brand Name/Generic Name Mechanism Year of approval 
Namenda/Memantine NMDA antagonist 2003 
Razadyne/Galantamine AChEI, NRM 2001 
Exelon/Rivastigmine AChEI, BuChEI 1996 
Aricept/Donepezil AChEI 1996 
Cognex/Tacrine AChEI, BuChEI 1993 
 
AChEI  = Acetylcholinesterase inhibition 
BuChEI  = Butyrylcholinesterase inhibition 
NRM = Nicotinicreceptor modulator 
NMDA = N-methyl d-aspartate 
1.5.2 Immunotherapy 
Immunization strategies, both active and passive, showed reduction of the Aβ plaque 
load and helped the restoration of cognitive deficits in transgenic mice (Bacskai et al., 
2002; Dodart et al., 2002; Gelinas et al., 2004; Klyubin et al., 2005). Several 
supportive evidences suggest immunotherapy as one of the most promising therapeutic 
strategies to treat AD. As a straightforward vaccination approach, Schenk and 
colleagues immunized APP transgenic mice with the Aβ aggregated form of Aβ1-42 
(Schenk et al., 1999). This strategy later paved the way for a passive immunization 
approach, where, for the first time, Dodart et al and Kotilinek treated APP transgenic 
mice with amyloid specific antibodies (Dodart et al., 2002; Kotilinek et al., 2002).  
 
1.5.2.1 Active immunization 
Direct immunization with synthetic Aβ aggregates was the first immunotherapeutic 
approach with respect to AD (Schenk et al., 1999). Strikingly, the AD pathology was 
reversed among the treated transgenic mice compared to the control group. The mode 
of action involves activation of microglia and stimulation of T and B-cell 
lymphocytes. Unlike the amyloid hypothesis, this immunotherapy approach was easily 
reproduced by other groups, who published similar results with some proposals on the 
underlying mode of action (Janus et al., 2000; Morgan et al., 2000). Short fragments 
conjugated with carrier protein were also used in active immunization, which triggers 
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B-cells to produce antibodies and stimulates T helper cells, leading to B-cell 
maturation that is mediated by cytokines (Sigurdsson et al., 2001). This approach 
minimizes the risk of T-cell response to Aβ. These studies suggested that the entire Aβ 
peptide was not needed to treat AD. 
 
In 2002, Elan pharmaceuticals and Wyeth Corporation jointly conducted a phase IIa 
clinical trial with AN-1792 (pre-aggregated synthetic Aβ1-42) with QS-21 adjuvant. 
The trial was suspended due to adverse response to the peptide vaccine. A small 
number of patients (18 out of 300), involved in the trial had symptoms resembling 
meningoencephalitis and microhemorrages (Bowers and Federoff, 2002; Munch and 
Robinson, 2002; Orgogozo et al., 2003). According to the report, the patients had less 
number of plaques compared to AD controls in the neocortex and reactive microglia 
around Aβ plaques (Ferrer et al., 2004; Nicoll et al., 2003). If meningoencephalitis and 
haemorrhages could be avoided, immunotherapy may be a potential approach to treat 
AD. As an aftermath effect, researchers were less interested to carry out with active 
immunization and passive immunization appeared as a potential and safer alternative. 
1.5.2.2 Passive immunization 
In the year 2000, Elan pharmaceuticals reported the first passive immunotherapy 
approach in the AD field. Bard and colleagues administered N-terminal specific (Aβ1-
15 and Aβ1-16) monoclonal antibodies (3D6 and 10D5) intraperitoneally into PDAPP 
(human Platelet derived growth factor driven-human APP transgenic) mice for six 
months on a weekly basis (Bard et al., 2000). The results showed that the antibodies 
crossed the blood brain barrier (BBB) and lead to significant reduction of plaques both 
in the cortex and hippocampus. Estimation of the amount of IgG entering the brain 
showed that 0.11% of injected IgG enters the brain within 1 hour after intraperitoneal 
administration, and remains in the brain for 72 hours (Banks et al., 2002). The 
disruption of amyloid plaques and clearance is carried out through Fc mediated 
phagocytosis by microglia (Bacskai et al., 2002). Bard et al and Bacskai et al, used N-
terminal specific antibodies, which can bind to the fibrils of amyloid that has 
protruding N-terminal sequence.  
 
DeMattos et al treated the identical PDAPP mice using mid-terminal specific (Aβ13-28) 
m266 antibodies and showed a reduction of Aβ deposition in the brain without binding 
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to the plaques (DeMattos et al., 2001). It is important to notice that the mechanism 
DeMattos proposed was due to the peripheral action of the antibodies, but not due to 
their entry into the brain. Intravenous injection of m266 into PDAPP mice resulted in 
1000 fold increased plasma levels of Aβ compared to the PBS treated group. They 
used m266 as a ‘capture antibody’, which binds to the mid-term region of Aβ, making 
it inaccessible for other endogenous proteins to bind and facilitates Aβ clearance in the 
liver. This mechanism of Aβ clearance by immunotherapy is also called the 
“peripheral sink hypothesis”. As per the peripheral sink hypothesis, the main role of 
these antibodies is to shift the equilibrium between soluble and aggregated Aβ 
assemblies towards soluble forms which further facilitates Aβ clearance. Similarly, the 
peripheral sink could also be observed with molecules like curcumin and phenolics, 
which can cross the BBB. These molecules bind to Aβ oligomers and fibrils to 
destabilize the complex leading to disaggregation of Aβ aggregates both in vitro and in 
vivo (Yang et al., 2005).  
 
In the year 2002, the same group treated PDAPP mice with the same antibodies 
(m266), and reported a reversal of memory deficits within one day after injection 
(Dodart et al., 2002). The improvement of cognition was found with unaltered Aβ 
plaque burden in the brain. Authors hypothesized the effect may be due to the removal 
of soluble Aβ fractions from the brain.  
1.5.2.2.1 Passive immunization with naturally occurring antibodies 
For the past thirty years, intravenous immunoglobulins (IVIG) have been used to treat 
some diseases related to immunological background like autoimmune disease and 
immunodeficiency. The FDA has approved the treatment for primary 
immunodeficiencies, Kawasaki syndrome, B-cell chronic lymphocyctic leukemia 
(CLL), and bone marrow transplantation.  
 
Previously our group and others reported that the naturally occurring autoantibodies 
against Aβ (NAbs-Aβ) are reduced in AD patients, which could interfere with fibril 
formation and reduce neurotoxicity (Du et al., 2001; Du et al., 2003; Weksler et al., 
2002). Interestingly, IVIG preparations that are available have been shown to contain 
these NAbs-Aβ (Dodel et al., 2002). Very recently we have reported that the 
differences among IVIG preparation and storage conditions influence the amount of 
   INTRODUCTION 
 
   18 
NAbs-Aβ and to some extent differs upon their specificity towards Aβ1-40 and Aβ1-42 
(Balakrishnan et al., 2010). 
 
These autoantibodies are both fibril-specific and specific to toxic conformations of Aβ 
(O'Nuallain et al., 2008). Klaver and colleagues recently reported that some IVIG 
preparations have more monomer specific antibodies compared to oligomer specific 
antibodies (Klaver et al., 2009) and may also affect plaque burden and induce 
activation of microglia without increasing microhaemorrhages (Kellner et al., 2009).  
 
Three pilot studies have been conducted to investigate the effect of IVIG in AD 
patients. The results showed that 6 months of treatment decreased Aβ levels in the 
CSF and increased plasma levels of Aβ (Dodel et al., 2004; Relkin et al., 2008). Based 
on the current evidence, NAbs-Aβ, which are part of the IVIG preparations, may serve 
as a potential treatment option for AD (Britschgi et al., 2009; Solomon, 2007).  
 
The epitope region of NAbs-Aβ lies in the membrane bound C-terminal region of the 
Aβ (Balakrishnan et al., 2010). The rationale using monoclonal antibodies directed 
against Aβ protruding out of the membrane may be considered as an inappropriate 
target. This is because the physiological role of Aβ or the cleavage products are not 
completely understood yet. Considering this, NAbs-Aβ isolated from FDA approved 
IVIG preparations might be seen as a safer therapy for AD.  
 
1.5.3 Anti-inflammatory drug therapy 
In the year 1990, McGeer et al reported that the long-term treatment with anti-
inflammatory drugs for rheumatoid arthritis patients showed signs of decreased 
dementia (McGeer et al., 1990). After this finding, there were reports that showed that 
different Non-steroidal anti-inflammatory drugs (NSAIDs) could modulate the 
secretase activity, Aβ levels, and also improved cognition after in animal models.  
1.6 Potential targets to treat Alzheimer’s disease 
To summarise, since the Aβ peptide was sequenced in the year 1992, the century long 
senile plaque and dementia story faced a rollercoaster ride in the past two decades. 
These very short hydrophobic Aβ peptides have the potential to aggregate and form a 
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macroscopic fibrillar structures, these fibrillar Aβ were initially believed to be the key 
cause for AD. Several studies clearly show that the real causative agent of AD may 
range from a dimeric structure to soluble oligomers, protofibrils, insoluble higher 
aggregates to deposited fibrillar Aβ.  
 
Due to the highly dynamic aggregation pattern of Aβ, lack of research techniques to 
identify the real culprit that cause AD and thereby the right target to treat AD remains 
a concern. Likewise, with the current knowledge of the disease, though it is 
inadequate, there should be a rational and safer approach for diagnosis and treatment.  
 
With respect to the amyloid hypothesis, the possible molecular targets to treat AD 
could be, by influencing the aggregation rate or helping in disaggregation of toxic 
species, to shift the equilibrium from toxic species to soluble fractions that can be 
cleared and/or those that could bind to specific toxic Aβ forms and reduce receptor-
mediated phagocytosis. Additionally, targeting the machinery involved in the Aβ 
production, which involves modulators and/or inhibitors of the secretases, is another 
possible approach to treat the disease.  
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals and reagents 
Name Supplier 
1,1,1,3,3,3-Hexafluor-2-Propanol 
Acetic Acid, Glacial 99+% 
Bis-Tris 
D-MEM 
Di-Potassium hydrogenphosphate trihydrate 
Di-Sodiumhydrogen phosphate-Dehydrate 
Di-Sodiumhydrogen phosphate* 2 H2O 
DMSO 
Ethanol Absolute  
Formaldehyde, 37 wt % 
Formic acid, 88% 
Glycine  
Hydrochloric acid 1N 
2 X LDS sample buffer  
MemCode™  
Methanol 
Potassium Chloride 
Potassium dihyrogen phosphate 
Precast 10-20% SDS PAGE gels  
Roti® Block 
SilverXpress staining kit  
Sodium Acetate- Trihydrate 
Sodium bicarbonate 
Sodium Carbonate 
Aldrich 
Sigma 
Sigma 
Gibco 
Applichem 
Fluka 
Roth 
Sigma 
Merck 
Sigma 
Aldrich 
Roth 
Sigma 
Invitrogen 
Pierce 
Roth 
Fluka 
Merck 
Invitrogen 
CarlRoth 
Invitrogen 
Aldrich 
Roth 
Aldrich 
Sodium Chloride 
Sodium dihyrogen phosphate Hydrate 
Sodium Dodecyl Sulphate (SDS) 
Roth 
Roth 
Sigma 
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Sodium Hydroxide pellets 
Sodium phosphate* 7 H2O 
SulfoLink gel (UltraLink 
Sulphuric acid 99.99% 
Supersignal West Dura Substrate 
Thioflavin T 
Triton X-100 
Trizma™ Hydrochloride 
Acros 
Sigma 
Pierce 
Aldrich 
Pierce 
Sigma Aldrich 
Roth 
Roth 
 
2.1.2 Equipments and devices 
Name Supplier 
BioRad Mini-PROTEAN 3 Cell 
Bio-Rad Laboratories, Richmond CA, 
USA 
BIOTRAK II PLATE WASHER(C)4LN 
GE Healthcare, Chalfont St. Giles, 
England 
CO2-Inkubator CB210 Binder, Tuttlingen, Germany 
Densiometer GS-800 
Bio-Rad Laboratories, Richmond CA, 
USA 
Eclipse80i Durchlichtmikroskop Nikon GmbH, Langen, Germany 
Elektrophoresekammer E-H3 
Febikon GmbH, Wermelskirchen, 
Germany 
Filmentwickler Optimax Typ TR MS-Laborgeräte, Heidelberg, Germany 
Fluoreszensmikrokop Nikon GmbH, Langen, Germany 
Fluoreszensmikrokop TE2000 Nikon GmbH, Langen, Germany 
Geldryer Model 583 
Bio-Rad Laboratories, Richmond CA, 
USA 
Kippschüttler Rocky® 3D Fröbel Labortechnik, Lindau, Germany 
Laborwaage PCB Kern, Balingen-Frommern, Germany 
Magnet Dispergierer S Heidolph, Kelheim, Germany 
Magnetrührer Hei-Tec 
VWR International GmbH, Darmstadt, 
Germany 
Mikrotiterplatten-Photometer Infinite M 
200 
Tecan, Männedorf, Switzerland 
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Mikrozentrifuge 5415D Eppendorf, Hamburg, Germany 
Mikrozentrifuge Galaxy 16DH 
VWR International GmbH, Darmstadt, 
Germany 
Mini-Protean Tetra Cell 
Bio-Rad Laboratories, Richmond CA, 
USA 
MKR13 KühlThermoMixer HLC BioTech, Bovenden, Germany 
pH-Meter MP220 Mettler Toledo, Gießen, Germany 
PowerPac Universal Power Supply 
Bio-Rad Laboratories, Richmond CA, 
USA 
Präzisionswaage BE BK Satorius, Göttingen, Germany 
Reagenzglasschüttler 
VWR International GmbH, Darmstadt, 
Germany 
Rotationsmikrotom Microm HM 355 S 
Thermo Fisher Scientific, Rockford IL, 
USA 
Rotor für 15 u. 50 ml Röhrchen, Nr. 3046 Heraeus, Hanau, Germany 
Rotor für Reaktionsgefäße, Nr. 3332 Heraeus, Hanau, Germany 
Sicherheitswerkbank HERAsafe/KS12 Heraeus, Hanau, Germany 
Tischzentrifuge Biofuge Stratos Heraeus, Hanau, Germany 
Tischzentrifuge Megafuge 1.0 R 
Bio-Rad Laboratories, Richmond CA, 
USA 
Trans-Blot SD Semi-Dry Transfer cell Nikon GmbH, Langen, Germany 
Universal-Microscope ELWD 0.3 PeqLab, Erlangen, Germany 
UV/Vis-Spectrophotometer NanoDrop 
ND-1000 
Thermo Fisher Scientific, Rockford IL, 
USA 
Vakuumzentrifuge Speed Vac RC 1010 UVP, Upland CA, USA 
White Light Transiliminator Invitrogen, Carlsbad CA, USA 
Xcell II Blot Module 
Bio-Rad Laboratories, Richmond CA, 
USA 
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2.1.3 Antibodies 
2.1.3.1 Monoclonal antibodies 
 Name Epitope Supplier 
3D6 Aβ 1-5 Elan 
m266 Aβ 17-24 Lilly 
A11 Spherical Aβ oligomers Kayed 
4G8 Aβ 17-28 Calbiochem 
6E10 Aβ 1-16 Calbiochem, Covance 
5C3 C-terminal Aβ 1-40, but not Aβ 1-42 Calbiochem 
 
2.1.3.2 Secondary antibodies 
 Name Supplier 
Goat-anti-human antibodies HRP tagged Calbiochem 
Goat-anti-mouse antibodies HRP tagged Calbiochem 
Goat-anti-rabbit antibodies HRP tagged Calbiochem 
 
2.1.4 Polyclonal antibodies 
 Name Supplier 
Intravenous immunoglobulins Octagam/Octapharma, Germany 
Intravenous immunoglobulins Gammagard/Baxter, Germany 
Intravenous immunoglobulins Kiovig/Baxter, Germany 
Intravenous immunoglobulins Gammunex/Bayer, Germany 
Intravenous immunoglobulins Intratect/Biotest Pharma, Germany 
Intravenous immunoglobulins Pentaglobin/Biotest Pharma, Germany 
Intravenous immunoglobulins Sandoglobin/CSL Behring, Germany 
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2.1.5 Cell culture supplements 
 
 Name Supplier 
DMEM  Invitrogen, Karlsruhe, Germany 
F12 Medium Invitrogen, Karlsruhe, Germany 
Fetal Bovine Serum Invitrogen, Karlsruhe, Germany 
Penicillin  Invitrogen, Karlsruhe, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
Trypsin EDTA Invitrogen, Karlsruhe, Germany 
 
2.1.6 Buffers and standard solutions 
All reagent solutions were prepared using double distilled and deionized water from a 
deionization system (Millipore Q) if not indicated otherwise. 
PBS – phosphate buffered saline, pH 7.4 
• 150 mM Sodium chloride 
• 2.5 M Potassium chloride 
• 10 mM Sodium phosphate  
• 1.5 M Potassium phosphate dibasic 
• ELISA washing buffer  
1 X PBS tween (0.05% Tween 20) 
Well coating buffer  
• 0.1 M Sodium-bicarbonate buffer pH 9.6 
Immunoprecipitation buffer (TBS – Tris buffered saline pH 7.5) 
• 50 mM Tris 
• 150 mM Sodium chloride 
• 1 mM EDTA 
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2.2 Methods 
2.2.1 Amyloid oligomer preparation  
2.2.1.1 Amyloid beta monomers 
Aβ1-42 tends to aggregate faster than Aβ1-40. In order to avoid aggregation, freeze-thaw 
procedure should be avoided as much as possible. DMSO keeps the peptide in 
monomeric state, for experiments where one needs monomeric forms of Aβ, DMSO is 
the ideal solution to resuspend the peptide. DMSO treated peptides should not be used 
for Dot blots. HFIP treatment is another alternative, if the peptides are not used 
immediately for the cell culture experiments. 
2.2.1.2 Amyloid beta dimer enrichment 
To get enriched dimers, N-terminal cysteine-containing Aβ1-40 should be used. Due to 
rapid aggregation ration cysteine tagging could not be used for Aβ1-42 and therefore 
Aβ1-42 dimers are not easily prepared. Lyophilized peptides should be dissolved in 1 X 
PBS for dimerization followed by the monomerization (to avoid solubility issues, 
peptides were incubated for 15 minutes (mins) in an ultrasound water bath with 65°C). 
During the preparation turbidity is normal, but precipitation or larger aggregates was 
avoided. Subsequently the peptide solution was centrifuged at 12,000 rpm for 10 mins 
at +4°C to get rid of the precipitate. The resulting supernatant was the quantified using 
Nano drop (2.2.8.2). The peptide solution was incubated at 37°C for 3 hours on a 
heated shaking block (900 r.p.m). 2 µl of ammonia solution was added to stop the 
oligomerization by bringing the pH to approximately 10. Alternatively, incubated 
peptide solutions were used for the experiments or immediately transferred to -80°C 
freezer for storage.  
2.2.1.3 Preparation of mutant Aβ trimer 
Trimer preparation were exclusively done by two point mutations at the C-terminal 
end of the peptide Aβ1-40; G29,33I. Resuspending the peptide in Sodium carbonate buffer 
of pH 9.6 brings trimeric structure which is stable for at least 2 weeks at +4°C, 
dissolving the peptide in other buffers will make them aggregated.  
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2.2.1.4 Preparation of toxic Aβ oligomers 
Preparation of toxic Aβ oligomers were performed as described by Kayed et al (Kayed 
et al., 2003). Briefly, 200 µg of Aβ1-42 were dissolved in 200µl of HFIP. Throughout 
the incubation steps, HFIP and HFIP containing solutions were handled under the 
ventilated hood. The peptide dissolved in HFIP was evaporated at room temperature 
(approx. 5-6 hours) or carefully lyophilized without drying the peptide. The peptide 
was then dissolved to obtain 1 mg/ml concentration of water + HFIP (25% v/v), and 
incubated for 2 days at 37°C with Teflon-coated magnetic stirrer with 900 rpm. The 
evaporated volume was then made up using MQ water and used for toxicity 
experiments immediately. 
Samples were prepared with all possible combinations of parameters mentioned above. 
Identical samples were prepared in the same vial to avoid pippetting error, evaporation 
of sample due to small volumes etc., Peptides incubated for particular time points were 
stored by freezing in -80°C or leaving them at +4°C after addition of Ammonia.  
2.2.2 SDS-Polyacrylamide gel electrophoresis (PAGE) and blotting 
Ready to use pre-cast gels were set in electrophoresis cell chamber (BioRad), filled 
with respective running buffers for 4-12% Bis-Tris gels or 10-20% Tricine gells. The 
power supply Power Pac (BioRad) was set to constant voltage at 125 V for 55 mins or 
until the sample dye reached the bottom of the gel (according to manufacturers’ 
instructions). 
2.2.3 Western blotting 
Nitrocellulose transfer membrane was washed with distilled water and soaked in 
blotting buffer. Gels were carefully removed from the plates. The transfer membrane 
was placed on the gel between two filter papers soaked with blotting buffer and three 
sponges on both sides and placed on the transfer membrane. The sandwich was placed 
in the blotting chamber filled with blotting buffer and with an ice cube block. The 
proteins were transferred from the gel to the transfer membrane for 2 hours at constant 
400 mA. 
2.2.3.1 Blocking procedure 
The transfer membrane was washed twice with PBS, MemCode stain was added and 
incubated for 2 mins followed by washing thrice with distilled water before adding 
   MATERIALS AND METHODS 
 
   27 
destain solution. This procedure is to check the transfer of proteins. Later stain erase 
solution was added and incubated until the stain was removed. The membrane was 
then boiled for 10 mins in PBS before blocking to increase the signal. The membrane 
was blocked for 1 hour at room temperature or overnight at +4°C in Superblock 
blocking buffer.  
2.2.3.2 Primary antibody incubation 
Monoclonal antibodies were diluted 1:4000 dilution or as recommended by the 
providers in Roti-block blocking buffer. Transfer membranes were incubated for 2 
hour at room temperature or at +4°C overnight.  
2.2.3.3 Secondary antibody incubation 
Followed by the incubation with the primary antibody, the membrane was washed 4 
times with PBS + 0.5% Tween for 10 mins each wash. After washing the membrane, it 
was incubated with the appropriate horseradish peroxidase (HRP)-conjugated second 
antibody at 1: 20,000 dilution in PBS + 0.5% Tween for 1 hour at room temperature.  
2.2.3.4 Detection 
Proteins were visualized by enhanced chemiluminescence (super signal) following the 
manufacturer’s instructions. The signals were exposed on X-ray films for an 
appropriate time and the films were developed using a film developer machine.  
2.2.4 Dot blotting 
Dot blotting has advantage of detecting conformational epitopes and therefore an 
effective technique to study conformational antibodies. 2 µl of Aβ peptides (1µg/ml) 
dissolved in the respective buffer according the oligomerization protocol were directly 
dotted onto a nitrocellulose membrane. The membranes were air-dried and incubated 
for 1 h at room temperature in blocking solution (Roti block, blocking solution), 
followed by an incubation step with anti-Aβ specific antibodies (1:250,000 dilution). 
Membranes were washed intensively four times with blocking solution and then 
incubated for 2 h in HRP-tagged antibodies directed at specific species of the primary 
antibody in blocking solution. Super Signal substrate was added and incubated for 3 
mins followed by washing with deionized water and signal was developed. 
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2.2.5 Immunoprecipitation 
Similar to Dot blotting, Immunoprecipitation has the advantage of allowing 
conformational antigen-antibody interaction. 5µg of antibodies and 3µg of specific Aβ 
enriched species in 100 µL IP buffer (TBS buffer pH 7.2) were incubated at +4°C 
overnight with end-over-end rotation. 100 µl of Protein G column slurry was washed 
twice with IP buffer followed by one wash with 1 X Roti block blocking buffer and 
incubated at +4°C overnight end-over-end. Blocking protein G slurry was then washed 
with IP buffer prior to the addition of antigen-antibody complex. This complex was 
incubated at room temperature for 1 hour with end-to-end rotation. After the 
incubation, the complex was washed 5 times with IP buffer followed by centrifugation 
at 13,000 g. 2 X LDS sample buffer and 1 X reducing agent was added to the slurry 
and boiled for 10 minutes with occasional vortex. Samples were then loaded over 10-
20% Tricine gel (Invitrogen) and electrophoresed for 90 mins. 
 
The gel was then transferred over Nitrocellulose membrane (0.2µM) for 2 hours at 200 
mA. Protein bands over the transferred membrane were then visualized by memcode 
(Invitrogen). Membrane was then boiled for 5 mins with 1 X PBS followed by 1 X 
Roti block blocking buffer for 1 hour. 2 µg of anti- Aβ antibodies were added and 
incubated with constant shaking at 4°C, overnight. Membrane was washed 5 times 
with 1 X PBS with 0.05% Tween prior to the addition of secondary antibody tagged 
with HRP and incubated for 1 hour at room temperature. Super Signal substrate 
(Pierce, Germany) was added and incubated for 3 mins followed by washing with 
deionized water and signal was developed.  
2.2.6 Silver staining 
Silver staining provides an easy method to detect protein staining with high sensitivity 
with the lowest background, especially Aβ oligomers. Electrophoresed gels were 
stained using SilverXpress staining kit according to manufacturer’s instructions.  
2.2.7 ELISA 
2.2.7.1 Antibodies quantification ELISA  
96 wells high binding plates were coated with Aβ peptides and incubated for 2 hours 
at 37°C in CO2 incubator (5% CO2). Plates were blocked with a commercial blocking 
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buffer; incubated overnight. Standard antibodies and diluted serum samples were 
added to the plates after 4 washing cycles after blocking step and incubated for 4 hours 
at 37°C in CO2 incubator. Plates were washed with 4 washing cycles with ELISA 
plate washer with washing buffer.  
HRP tagged anti-human secondary antibody (1:4000 dilution in Superblock) was used 
as detection antibody, plates were washed thoroughly (5 washing cycles); TMB being 
the substrate. Reaction was stopped using Sulphuric acid and OD read at 450 nm. 
2.2.7.2 Indirect ELISA 
Indirect ELISA is one of the best tools to study conformational antigen-antibodies 
interaction. Briefly, 96 well microtiter plates were coated with 100µl of amyloid beta 
peptide of concentration 5µg/mL with 100 mM Sodium Bicarbonate buffer (pH 9.6) 
and incubated overnight at 4°C. Discarding the content, plates were then coated with 
Super block (300µL), blocking solution and left overnight at 4°C. Plates were washed 
5 times with PBS containing 0.05% of Tween and stored in the fridge.  
2.2.7.3 Isolation of Aβ-specific auto-antibodies from IVIGs 
NAbs-Aβ were isolated from IVIG using affinity chromatography (Balakrishnan et al., 
2010). An affinity purification column was packed by SulfoLink gel (UltraLink, 
Pierce), couple with synthetic N-terminal cysteine-added Aβ (0.6 mg/ml) and 
resuspended in coupling buffer (50 mM Tris, 5 mM EDTA, pH 8.5). Blocking with 
cysteine (50 mM; resuspended in coupling buffer) and washing (1 M NaCl) preceded 
IVIG sample application. NAbs-Aβ were recovered with elution buffer (100 mM 
glycine, pH 2.5), immediately neutralized and used for further experiments.  
2.2.8 Protein analysis 
2.2.8.1 Alanine scanning mutagenesis 
To characterise the epitope further, widely accepted alanine scan mutagenesis was 
used, where the natural amino acid sequence was replaced with Alanine (CH3 side 
chain) as a site-specific point mutation. The rationale behind Alanine-scanning 
mutagenesis is that all interactions of a side chain except for Cβ are eliminated (Tsiang 
et al., 1995). 
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2.2.8.2 Protein quantification using Nanodrop 
Protein concentration was measured by A280 nm on a Nanodrop UV/visible 
spectrophotometer (Nanodrop®, US), using the respective buffer as blank and entering 
the Molar extinction coefficient and molecular weight of the protein/peptide.  
2.2.8.3 Protein quantification using BCA-kit  
Total protein concentration of brain extracts were quantified using BCA kit according 
to manufacturer’s instructions (Pierce). 
2.2.9 Cell culture 
2.2.9.1 Maintenance of cell lines 
N2A and BV2 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) 
and F12 medium, respectively, supplemented with heat-inactivated 10% FBS, 100 
U/ml Penicillin, and 100 µg/ml Streptomycin. Cells were grown at 37°C, 5% CO2 
aeration and 95% humidity. Cell culture work was performed under a sterile laminar 
flow safety cabinet using pre-sterilized materials and solutions. Cell splitting and 
passaging was performed twice a week obtaining confluency. Cells were washed with 
sterile PBS to remove cell debris and residues of FBS that might inhibit trypsin 
activity and incubated with 2 ml trypsin EDTA solution (0.5 mg/ml trypsin and 0.22 
mg/ml EDTA) for 5 minutes at 37°C. Trypsin cleaves extracellular adhesion proteins 
and EDTA binds Ca2+ ions required for cell-cell adhesions formed by cadherins and 
thereby supports cell detachment. Cells were resuspended in 10 ml medium containing 
FBS and centrifuged at 500Xg for 5 mins. The pellet was resuspended in the 
respective medium and cells were seeded as single cell suspension in a dilution of 
1:10. The medium was changed every two days to provide fresh nutrients, to remove 
toxic products and to prevent pH changes, which are indicated also by the pH indicator 
dye (phenol red) included in the medium. 
2.2.9.2 Cell toxicity assay MTT assay (Aβ toxicity) 
Cell proliferation was assessed by monitering the conversion of MTT to formazan. 
Mitochondrial dehydrogenase enzymes catalyze the reduction of MTT, which is 
therefore a measure of cell viability (Mosmann, 1983). For Aβ induced toxicity assay, 
cells were seeded at seeding densities of approximately 1x104 cells/ml into 24 well 
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plates and allowed to adhere for 24 h. Prepared Aβ monomers, oligomers or mutant 
oligomers were mixed in a serum-free medium before treating the cells (Kayed et al., 
2003). After 48 hours of treatment, cell viability was assessed by adding 500 µl of 
MTT (5mg/ml in PBS) and subsequently incubated for 4 hours. Medium was removed 
and cells were dissolved in sterile DMSA (500 µl) by incubated at 37°C for 30 min. 
The resulting absorbance at 550 nm was measured with a plate reader. Only the inner 
rows of the plate were used for the studies considering the medium evaporation rates 
at the periphery. The growth curve was constructed by plotting absorbance (blanked 
with DMSO) against time.  
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3 RESULTS 
3.1 Epitope characterization 
3.1.1 Comparison of commercial IVIG preparations for Aβ  specific 
antibodies 
Intravenous immunoglobulins (IVIG) are FDA-approved therapeutic agents for 
inflammatory and autoimmune disorders. Seven commercially available IVIGs (Table 
2) were compared with respect to their differences in Aβ binding efficiency, using 
indirect ELISA. Two different lengths of Aβ peptide were used in the study Aβ1-40 and 
Aβ1-42. Commercially available IVIG showed considerable differences in the binding 
toward both Aβ peptides (Aβ1-40 (Figure 5) and Aβ1-42 (Figure 6)). 
 
Table 2 Different brands of commercial IVIG preparations used in the study 
 
IVIG Product IgG (mg/ml) Manufacturer 
Gammagard 50 Baxter, Germany 
Gammunex 100 Bayer, Germany 
Intratect 50 Biotest Pharma, Germany 
Kiovig 50 and 100* Baxter, Germany 
Octagam 50 Octapharma, Germany 
Pentaglobin 50 Biotest Pharma, Germany 
Sandoglobulin 50 CSL Behring, Germany 
 
* Kiovig used for ELISA using Aβ1-42 were supplied as 100 mg/ml concentration. 
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Figure 5 Comparison of binding affinities of commercial IVIG towards Aβ1-40. Optical density 
represents binding of NAbs-Aβ towards Aβcys.1-40, measured using an ELISA coated with Aβcys.1-40. To 
account for the specificity of the technique, a monoclonal antibody specific for the mid-terminal region 
was added as a positive control and a non-specific monoclonal antibody was included as a negative 
control. 
 
 
Figure 6 Comparison of binding affinities of commercial IVIG towards Aβ1-42. OD represents the 
ELISA data demonstrating binding of NAbs-Aβ towards Aβ1-42. Along with IVIG preparations, Aβ 
specific and non-specific monoclonal antibodies were used as positive and negative controls, 
respectively. 
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Among all IVIG products compared, Octagam and Gammunex showed the strongest 
binding to Aβ1-40 and Aβ1-42, reflecting the presence of more Aβ specific NAbs in their 
IgG pool. Sandoglobulin, Gammagard and Intratect showed similar binding 
efficiencies. Kiovig had the lowest concentration of NAbs-Aβ and hence the lowest 
binding affinity to Aβ1-40, and moderate binding affinity towards Aβ1-42. On the 
contrary, Pentaglobin showed the presence of more Aβ1-40 specific NAbs than to Aβ1-
42 (Balakrishnan et al., 2010). 
 
3.1.2 Determination of the Aβ domain-specificity of NAbs-Aβ   
To identify the binding domain of Aβ that is recognized by the Aβ-affinity purified 
NAbs (NAbs-Aβ), the full-length sequence of Aβ1-40 was compared with shorter 
truncated versions of the peptide using indirect ELISA. The peptide sequences used 
for the study comprised of: the full-length Aβ1-40, reverse sequence of Aβ40-1, 
truncated N-terminal (Aβ1-15), mid-terminal (Aβ10-28), and two C-terminal sequences 
(Aβ20-38 & Aβ25-40) of Aβ (Table 3). The full length and reverse sequences were used 
as positive and negative controls respectively. Other sequences had a prerequisite of 
15 amino acids length and were chosen to represent different domains of Aβ.  
Aβ20-38 was included in the study following a previous report where Aβ21-37 was shown 
to be the functional epitope for NAbs-Aβ (Przybylski M, 2008). NAbs-Aβ recognized 
Aβ25-40 better than the rest of the domains of Aβ (Balakrishnan et al., 2010) (Figure 7). 
Interestingly, Aβ20-38 that includes the same sequence as in Aβ25-40 showed less 
binding.  
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Figure 7 NAbs-Aβ recognize C-terminal Aβ  fragment. Indirect ELISA, peptides were coated on 
plates and affinity NAbs (1mg/mL) were diluted to 1:12500 with duplicates. Bars represent the 
optical density measured at 450nm after the treatment with HRP labelled goat-anti-human secondary 
antibodies followed by addition of TMB substrate. Figure represents the one of the dilutions among 
three dilutions with consistent pattern and experiment was repeated thrice.  
Table 3 Sequences of Aβ used in the experiment 
 
Representation of human Aβ amino acid sequence in single letter code. The Aβ sequences used in 
the experiments are shown in white colour. The amino acids that are present in the original Aβ sequence 
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and excluded in the truncated Aβ sequences that are not used in the experiments are intentionally 
dimmed using blue letters.  
  
3.1.3 Alanine scanning mutagenesis at the position 25 to 27 of Aβ  C-
terminal end decline their role as epitope 
Alanine scanned Aβ1-40 peptides, Aβ1-40; G25A, Aβ1-40; S26A and Aβ1-40; N27A, were 
analyzed used indirect ELISA. Additionally, truncated Aβ23-31 and Aβ1-40; S26S, where 
naturally occurring amino acid form Levo was substituted with Dextro isomers, were 
included in the studies (Figure 8).  
 
 
Figure 8 Alanine scanning mutagenesis at beginning of the C-terminal Aβ  shows no significant 
decline in NAbs binding. Indirect ELISA, peptides were coated on plates and affinity NAbs (1mg/mL) 
were diluted (1XPBS) to 1:1000 with duplicates. Bars represent the optical density measured at 450nm. 
Figure represents the one of the dilutions among three dilutions with consistent pattern in three 
independent experiments.  
 
Results showed that the Alanine substitution at positions 25, 26 or 27 did not affect the 
binding of NAbs. Moderately increased binding was found with Aβ1-40; N27A where 
replacing polar amino acid Asparagine was exchanged to non-polar Alanine. On the 
other hand, neither the replacement of L-Serine to D-Serine nor the Serine to Alanine 
affected the binding of NAbs-Aβ towards them. Interestingly, shorter Aβ23-31 fragment 
showed relatively low binding compared to N27A mutant. Results suggested that the 
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NAbs-Aβ epitope region on Aβ was not between Aβ 1-27 as shown in the schematic 
diagram  
 
Figure 9 Schematic diagram of Aβ sequence recognized by NAbs-Aβ. Figure displays the full-length 
Aβ amino acid one letter sequence and the expected epitope region in black colour with green glow. 
Alanine scanned positions tested in the experiment are given in yellow colour, where red coloured glow 
indicates that those positions are not representing the epitope. Alanine scans at positions 25, 26 and 27 
suggests that these three amino acids are not representing the epitope region on Aβ detected by NAbs-
Aβ. Aβ sequences that are not used in the experiments are intentionally dimmed using blue letters.  
3.1.4 NAbs-Aβ specifically recognizes the C-terminal end of Aβ 28-42 
The far C-terminal end of Aβ sequence was analyzed to further explore the epitope 
region. Truncated Aβ42 was preferred to truncated Aβ40 to avoid the extreme 
shortening of the peptide’s length in the studies. The binding of NAbs-Aβ with far C-
terminal end comparing 3 shorter peptide sequences Aβ26-42, Aβ28-42 and Aβ30-42 was 
determined using indirect ELISA. Synthetic Aβ30-42 had solubility issues while 
resuspending in the well coating buffer; this may be due to the presence of highly 
hydrophobic nature of C-terminal sequence of the Aβ peptide. 
 
 
Figure 10 Comparison of far C-terminal Aβ  shows increased binding of NAbs (1: 250 dilution 
with duplicates). Figure represents ELISA data from one of the dilutions among three dilutions with 
consistent pattern in three independent experiments. 
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Data (Figure 10) demonstrates that the NAbs-Aβ recognize Aβ28-42 better than Aβ1-40, 
Aβ26-42 and Aβ30-42, which is in line with the previous Alanine-scanning mutagenesis 
results (Figure 8).  
3.1.5 Conformation specificity of Aβ-specific NAbs 
To extend the understanding of the NAbs-Aβ binding on the Aβ, alanine-scanned C-
terminal sequences were compared using indirect ELISA. To avoid the solubility 
issues observed with Aβ30-42 and to maintain the prerequisite of at least 14 amino acids 
length, the alanine scans were done at positions 30, 33 and 35 of Aβ28-42, respectively. 
Despite the fact that alanine at position 30 could not represent the epitope region, 
glycine was substituted to find out whether the improved solubility helps NAbs-Aβ 
binding. Accordingly, alanine at position 30 was exchanged to glycine. Alanine scan at 
35th position was done to determine whether methionine represent the Aβ epitope 
region for NAbs-Aβ. Additionally, to check the influences of the coating buffer, two 
different coating buffers were used. For this study, PBS (pH 7.4) that helps Aβ 
aggregation and 0.1 M Sodium carbonate buffer (pH 9.6), a pH range that restrict Aβ 
aggregation were used (Balakrishnan et al., 2010). The full-length and truncated forms 
of Aβ were coated with two different well coating buffers with different pH. Alanine 
scanned peptides were coated with 0.1 M Sodium carbonate. 
 
 
Figure 11 Comparison of Alanine-scanned C-terminal Aβ  and effect of the pH of well coating 
buffer. Indirect ELISA, for Aβ1-40 and Aβ25-40 peptides we used PBS (pH 7.4) and 0.1M Sodium 
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carbonate buffer (pH 9.6) as well coating buffer. The alanine-scanned peptides were coated with 0.1M 
Sodium Carbonate buffer and affinity NAbs (1mg/mL) were diluted with 1XPBS to 1: 250 with 
duplicates. Bars represent the optical density measured at 450 nm after the treatment with HRP labelled 
goat-anti-human secondary antibodies followed by addition of TMB substrate. Figure represents the one 
of the dilutions among three dilutions with consistent pattern in three independent experiments.  
 
The ELISA data shows that the different coating buffers did not influence the binding 
of NAbs-Aβ towards the Aβ. Interestingly, the substitution of Alanine at position 30 
of the Aβ peptide increased the binding of affinity purified NAbs. Increased binding of 
the antibodies towards the truncated peptide may be due to its effective display of the 
epitope. But according to the (Figure 11), when compared to the other truncated 
alanine-scanned peptides Alanine replacement at the position 30 increases the binding 
of the NAbs-Aβ. 
3.1.6 Influence of cysteine in NAbs-Aβ binding  
Previous experiment suggested the possibility of either the Aβ oligomerization or the 
conformational change due to hydrophobic amino acid inclusion might influence the 
NAbs-Aβ binding. Further, experiment was designed to investigate the effect of 
oligomerization and the possible conformational changes due to non-natural amino 
acid inclusion. Cysteine was included at the N-terminal sequence of Aβ. Cysteine was 
chosen to induce oligomerization because of its tendency to form cystine disulphide 
bonds (O'Nuallain et al., 2010). Another rationale behind the choice of cysteine was its 
usage in the Aβ affinity purification columns (Balakrishnan et al., 2010) see section 
(2.2.7.3). Influence of the cysteine was studied by comparing WT Aβ to N-terminal 
cysteine added sequences. For this study, NAbs-Aβ binding efficiencies towards WT 
and N-terminal sequences of full length (Aβ1-40 and N-cys-Aβ1-40), (Aβ1-15 and N-cys-
Aβ1-12), mid-terminal (Aβ10-28 and N-cys-Aβ10-38), and C-terminal Aβ sequences (Aβ20-
38, Aβ25-40, Aβ28-42, and N-cys-Aβ25-40), were compared.  
In addition, Aβ20-38; V39C and Aβ28-42;I31A,L34A, V40A were included in the studies. 
Previously Aβ20-38 showed less binding towards NAbs-Aβ compared to Aβ25-40, which 
suggested valine at position 39 or 40 might either contribute as epitope or assist 
oligomerization (Figure 10). Addition of cysteine was expected to improve the 
aggregation by forming inter-molecular disulphide bonds between cysteine residues 
and thus help oligomerization. Cysteine was added at 39th position of Aβ20-38; (Aβ20-
38;V39C) to explore whether the binding of NAbs-Aβ could be restored. Alanine 
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scanning was done on three hotspots (Aβ28-42;I31A,L34A sequence) to find whether any 
one of the three amino acids represents the epitope region for NAbs-Aβ. Reverse 
sequence of Aβ (i.e. Aβ40-1) was included as negative control.  
The rationale behind Alanine-scanning mutagenesis at 31, 34 and 40th positions of Aβ 
peptide is that, NAbs-Aβ recognized sequence between 30-40 in our previous 
experiments (Figure 11). Alanine substitution at positions 33 and 35 did not influence 
the binding of the NAbs-Aβ. Glycine, with H as its functional group, cannot act as an 
epitope and is present at 30th, 33rd, 37th and 38 positions. Replacement of Methionine 
at position 35 to Alanine did not influence NAbs-Aβ binding (Figure 11). As per 
Petkova et al’s observation, Isoleucine at the position 32, Valine at positions 36 and 39 
are involved in aggregation process and we assumed these amino acids would not be 
free to represent an epitope.  
  
Figure 12 Comparison of truncated peptides with and without cysteine and suspected epitope 
region. Indirect ELISA, peptides were coated on 96 well plate with 0.1M Sodium carbonate buffer (pH 
9.6) as well coating buffer. The affinity NAbs-Aβ (1mg/mL) were diluted with 1XPBS to 1: 4000 with 
duplicates. Bars represent the optical density measured at 450 nm after the treatment with HRP labelled 
goat-anti-human secondary antibodies followed by addition of TMB substrate. Figure represents the one 
of the dilutions among three dilutions with consistent pattern in three independent experiments.  
 
The ELISA data demonstrates the influence of the additional cysteine residue at the N-
terminal end of Aβ for the recognition of NAbs-Aβ (Figure 12). N-terminally cysteine 
added C-terminal Aβ peptides were recognized better by the NAbs-Aβ compared to 
the N-terminal sequence with or without the cysteine. This suggested that both the C-
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terminal sequence and the Cysteine are important for the NAbs binding. In turn, N-
terminal cysteine helps the peptide to oligomerize, suggesting NAbs-Aβ recognize 
oligomerized forms of the Aβ peptide. In addition, Aβ28-38 was recognized by the 
NAbs-Aβ with a cysteine replacement at the 39th position. This confirms our 
assumption that the Valine at 39th or 40th positions helps in oligomerization and does 
not act as epitope. This could also be the reason why Aβ20-38 was not recognized by the 
NAbs-Aβ. Alanine scanning mutagenesis at the positions 31, 34 and 40th position did 
not affect the NAbs binding suggesting those three positions are not representing the 
epitope region.   
 
Figure 13 Schematic diagram of Aβ sequence recognized by NAbs-Aβ. Figure displays the full-
length Aβ amino acid one letter sequence and the expected epitope region in black colour with green 
glow. Alanine scanned positions tested in the experiment are given in yellow colour, where red coloured 
glow indicates that those positions are not representing the epitope. Alanine scans at positions 31, 34 
and 40 suggests that these three amino acids are not representing the epitope region on Aβ detected by 
NAbs-Aβ. Aβ sequences that are not used in the experiments are intentionally dimmed.  
 
In summary, the results obtained in these experiments left three possible amino acids 
positions as potential epitope region (Figure 13). 
3.1.7 Isoleucine at position 32 plays a crucial role as epitope region 
for NAbs-Aβ binding 
To further understand the NAbs-Aβ binding towards Aβ addtion of cysteine, alanine 
scan mutagenesis and amino acid substition analysis were performed. Full length Aβ 
with additional cysteine at N-, C- and both N & C-terminal were analysed to study the 
influence addition of cysteine at the C-terminal as a continuation of the previous 
experiment .  
Truncated Aβ28-42 with three alanine substiutions at positions 32, 35 and 40 was 
included in the study along with WT Aβ1-40 and Aβ40-25 as positive and negative 
controls respectively. The rationale behind the triple mutant Aβ28-42; I32A, M35A,V40A are: 
previous results suggested that the epitope region should be between 30-40 (Figure 
12), Glycine at positions 30, 33 and 37 cannot act as an epitope, positions 31 and 34 
are not epitope according to the alanine-scanning . Valine at 40th position was included 
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in the studies, considering its role in oligomerization, whose exclusion might affect the 
NAbs-Aβ binding. As another approach, a scrambled sequence of  Aβ28-42 was used, 
where a jumbled sequence except the epitope region could yield NAbs-Aβ binding. In 
this scrambled sequence, all the amino acids except the 31, 35 and 40th position amino 
acids were substituted with other amino acid with equal polarity and hydrophobicity.  
Further, glycine at positions 29 and 33 of full length Aβ1-40 was exchanged to 
isoleucine. Replacement was based on previous observation where binding 
substitution of hydrophobic amino acid alanine instead of glycine improved efficiency 
of NAbs-Aβ (Figure 11). Isoleucine was substituted to improve the hydrophobicity of 
the C-terminal end and thereby helping Aβ oligomerization. Previously, 
intramolecular salt bridge formation between aspartate and lysine was reported 
(Petkova et al., 2002). In this regard, full length Aβ1-40 with an exchange of positions 
between aspartate at 23rd position and lysine at 28th position were used. The rationale 
was to explore whether the distrubance of the salt bridge formation affect the NAbs-
Aβ binding. Additionally, lysine at 28th position was exchanged to aspartate on the full 
length Aβ1-40 sequence along with alanine-scans at positions 32 and 40. This triple 
mutation was used in the experiment to study whether inclusion of aspartic acid 
improves the NAbs-Aβ binding. 
 
 
Figure 14 Comparison of Alanine-scanned C-terminal Aβ  and cysteine addition at N & C-
terminals. Indirect ELISA, cysteine added, alanine-scanned, and scramble sequences peptides were 
coated with 0.1M Sodium Carbonate buffer. Affinity NAbs-Aβ (1mg/mL) were diluted with 1XPBS to 
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1: 250 with duplicates. Bars represent the optical density measured at 450 nm after the treatment with 
HRP labelled goat-anti-human secondary antibodies followed by addition of TMB substrate. Figure 
represents the one of the dilutions among three dilutions with consistent pattern in three independent 
experiments. 
 
Results clearly showed that the addition of cysteine to Aβ improved NAbs-Aβ binding 
compared to the WT Aβ (Figure 14). Despite the addition of cysteine improves the 
NAbs-Aβ binding, C-terminal cysteine added sequence showed less binding efficiency 
toward NAbs-Aβ. The triple alanine scanned sequence Aβ28-42; I32A, M35A,V40A showed 
remarkably less binding towards NAbs-Aβ. On the contrary, the binding efficiency of 
the NAbs-Aβ towards the scramble sequence was not completely abolished. Aβ1-
40;I32A,M35A,V40A. Interestingly, NAbs-Aβ showed comparatively high binding efficiency 
towards isoleucine substituted Aβ1-40;G29,33I. Both Aβ1-40;D23K,K28D and Aβ1-40;D23R,I32A,V40 
showed similar binding to NAbs-Aβ as WT Aβ1-40. The reverse sequence Aβ40-25 
showed less binding efficiency towards NAbs-Aβ. 
 
 
Figure 15 Dot blot showing Alanine scanning at position 32 replacing Isoleucine completely 
abolishes NAbs binding. The stripped blot was then treated with N-terminal specific 3D6 antibodies 
that recognize all the scanned peptides. Synthetic wild type and alanine scanned peptides (2µg) were 
dotted on Nitrocellulose membrane followed NAbs-Aβ treatment for O/N at 4°C, the same blot was 
treated with stripping buffer and incubated for 1 hour with 3D6.  
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To confirm the ELISA data where alanine substitution at 32nd position of Aβ 
decreased NAbs-Aβ binding, Dot blot analysis was done. For this study, full-length 
Aβ with alanine scans were done primarily at position 32. To find out whether the 
decreased binding was due to a single amino acid at a specific position or a collection 
of all three amino acids alanine scans were planned accordingly. Peptides Aβ1-40, Aβ1-
42, Aβ1-40;I32A, Aβ1-40;I32A,M35A, Aβ1-40;I32A,M35A,V40A, Aβ1-40;G29,33I, and Aβ1-42;G29,33I,A42I 
were analyzed using Dot blots (Figure 15).  
Results confirm that isoleucine at position 32 represent the epitope for NAbs-Aβ. 
Interestingly, all peptide sequences with alanine scan at 32nd position completely 
abolished NAbs-Aβ binding. Aβ1-40;G29,33I, and Aβ1-42;G29,33I,A42I and the positive 
controls Aβ1-40, and Aβ1-42 showed the expected signal. Removal of antibodies from 
the membrane and re-probing using N-terminal specific 3D6 antibodies showed the 
peptides were spotted on the membrane. In summary, epitope mapping clearly 
demonstrated the role of Lys28 and Ile32 by comparing a list of full length (Figure 16) 
and truncated peptides (Figure 17). Especially, Ile32 plays a very vital role as an 
amino acid representing Aβ epitope region for NAbs-Aβ. 
 
Figure 16 List of Full length peptides used and their binding signal to NAbs-Aβ. Truncated 
sequence with substitution mutations and signal intensity given by indirect ELISA using NAbs. 
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Figure 17 Truncated sequence with substitution mutations and signal intensity given by indirect 
ELISA using NAbs-Aβ 
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3.2 Oligomerization of Amyloid beta 
3.2.1 Inclusion of N-terminal cysteine helps Aβ  dimerization  
Data from previous experiments indicates addition of cysteine and there by increased 
Aβ, improves binding of NAbs-Aβ toward the Aβ. Further, experiments were 
designed to study the Aβ oligomerization driven by the addition of N-terminal 
cysteine to WT Aβ sequence. In this study, several parameters like, addition of 
cysteine, influence of pH of the solution, incubation time, storage parameters and 
physical force (like shaking or stirring) of the peptide solution were studied.  
 
After oligomerization experiments, ELISA and SDS-PAGE were performed to 
determine the NAbs-Aβ binding and approximate oligomeric form of every particular 
sample, respectively (Figure 18).  
 
 
Figure 18 Time course experiment: Aβ peptide treated with different parameters shows the NAbs-
Aβ recognize particularly N-Cys-Aβ1-40. 
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Abbreviation Expansion 
FW0N Fresh WT 1-40, 0 hours incubation. 
FC0N Fresh Cys-1-40, 0 hours incubation 
AC3F Acidic buffer, Cys-1-40, 3 hours & Frozen after incubation 
AC3N Acidic buffer, Cys-1-40, 3 hours & stopped with Ammonia 
AW3F Acidic buffer, WT 1-40, 3 hours & Frozen after incubation 
AW3N Acidic buffer, WT 1-40, 3 hours & stopped with Ammonia 
AC18F Acidic buffer, Cys 1-40, 18 hours & Frozen after incubation 
AC18N Acidic buffer, Cys 1-40, 18 hours & stopped with Ammonia 
AC24 Acidic buffer, Cys-1-40, 24 hours incubation 
AW24 Acidic buffer, WT 1-40, 24 hours incubation 
NC3F Neutral buffer, Cys-1-40, 3 hours & Frozen after incubation 
NC3N Neutral buffer, Cys-1-40, 3 hours & stopped with Ammonia 
NW3F Neutral buffer, WT 1-40, 3 hours & Frozen after incubation 
NW3N Neutral buffer, WT 1-40, 3 hours & stopped with Ammonia 
NC18F Neutral buffer, Cys 1-40, 18 hours & Frozen after incubation 
NC18N Neutral buffer, Cys 1-40, 18 hours & stopped with Ammonia 
NC24 Neutral buffer, Cys-1-40, 24 hours incubation 
NW24 Acidic buffer, WT 1-40, 24 hours incubation 
ASC18 Acidic buffer, Cys-1-40, 18 hours incubation with stirring  
ASW18 Acidic buffer, WT 1-40, 18 hours incubation with stirring  
NSC18 Neutral buffer, Cys-1-40, 18 hours incubation with stirring  
NSW18 Neutral buffer, WT 1-40, 18 hours incubation with stirring  
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Figure 19 Influence of different parameters on Aβ1-40 oligomerization after 3 hours incubation. Aβ 
with and without cysteine were incubated in acidic and neutral pH for 3 hours. Subsequently samples 
were electrophoresed and silver stained.  
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Figure 20 Influence of different parameters on Aβ1-40 oligomerization after 18 hours incubation. 
Aβ with and without cysteine were incubated in acidic and neutral pH for 18 hours. Subsequently 
samples were electrophoresed and silver stained to detect the oligomerization.  
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Figure 21 Influence of different parameters on Aβ1-40 oligomerization after 18 and 24 hours 
incubation. Aβ with and without cysteine were incubated in acidic and neutral pH for 18 and 24 hours. 
Subsequently samples were electrophoresed and silver stained to detect the oligomerization 
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3.3 NAbs–Aβ recognizes Aβ conformational epitope 
It was previously shown that NAbs-Aβ recognize C-terminus of Aβ peptide and binds 
to Aβ oligomers better than monomeric Aβ. Aβ undergo different conformations, in 
this regard, knowledge about the conformational epitope of NAbs-Aβ becomes 
crucial.To extend out the understanding of Aβ epitope, conformationally fixed Aβ 
peptides were analyzed. Click peptides or O-acyl isopeptide method were used to 
serve this purpose. Click peptides form amide bonds instead of peptide bonds and slow 
down the aggregation rate of the amyloid peptide (Sohma and Kiso, 2006). This 
property of click peptides thereby provide the conformational stability of Aβ and helps 
to study the antigen-antibody interaction.  
 
In this study, NAbs-Aβ binding towards conformationally stable truncated Aβ28-40 
peptides, particularly depicting linear, parallel, anti-parallel and fibrill like epitopes, 
were analyzed. In total 24 Aβ click peptides were used, which were named as Mini- 
Aβ (MA) peptides. Indirect ELISA was used to compare the NAbs-Aβ binding toward 
MA peptides. 
 
The conformationally stable truncated MA peptides described in this chapter were 
prepared by Dr. A. Roeder in the research group of, our collaborator, Prof. Dr. A. 
Geyer, Department of Peptide chemistry, Philipps-University of Marburg. Description 
of the preparation of the peptides are presented in the thesis of Dr. A. Roeder (Roeder, 
2012). The ideas and the results developed has been submitted for a patent application 
(R. Dodel, 2011). 
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Figure 22 Chemistry of MA peptides. Short peptides were designed according to the epitope domain 
recognized by NAbs-Aβ. Synthetic peptides were produced using click peptides to fix the conformation 
of the peptide stable. MA 01, 03, 04, 05, and 13-21 represent epitope region as linear, and rest of the 
peptide display dimeric conformations, respectively.  
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3.3.1.1 NAbs-Aβ recognize dimeric conformation better than 
monomers 
In order to identify the binding of NAbs-Aβ towards the first set of 12 MA peptides, 
MA 01 to MA 12 were compared using indirect ELISA. Considering the practical 
difficulties in synthesizing the click peptides for full length of Aβ, C-terminal 
sequences were chosen for the experiments. Additionally, the characterization (NAbs-
Aβ binding) of shorter form of Aβ peptides were done intended to develop a candidate 
for active vaccination approach.  
 
Figure 23 Chemistry of MA peptides 01-06  
MA 01 represents a linear Aβ29-40 peptide. MA 02 chemistry provides a flexible, 
dimeric, open-chain Aβ28-40 linked at the C-terminal end using click chemistry L-
Serine propargyl ether (Spe). MA 03 display monomeric linear Aβ28-40 sequence. 
Previous epitope characterization showed improved binding of NAbs-Aβ due to the 
inclusion of an hydrophobic amino acid at 33rd position of Aβ (Figure 11). To further 
study whether the similar effect could be obtained using L-tert-leucine (t-leucine), 
which is more hydrophobic compared to leucine, was used as MA 04. MA 05 also 
represent Aβ29-40 peptide with additional C-terminal proline derivative. MA 06 is a 
cyclic anti-parallel dimer with flexible linkers Spe and cis-4-Azido-L-proline (Azp). 
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The peptide strands can move against each other but remains in an anti-parallel 
alignment. The chemistry of MA 01-06 are given in the figure above (Figure 23). 
 
Figure 24 Chemistry of MA peptides 07-12 
The MA 07, 08 and 09 are the linear precursors of MA 10, 11 and 12 cyclic peptides. 
They are flexible dimers of the fragments Aβ30-38, Aβ29-39, Aβ29-41 and in their 
attributes similar to MA-02. The cyclic peptides MA-10, -11 and -12 are related to 
MA-06. The backbone of the peptides was directly incorporated with a more rigid 
linker. The linker 6,5-Bicyclic thiazolidine lactam (Pli=cat) is a β-turn mimetic, 
guiding the conformation of the peptide towards a β-sheet.  
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Figure 25 Comparison of NAbs-Aβ binding towards MA 01 to 12. Bars represent the optical density 
at 450, measured using indirect ELISA, an index of NAbs-Aβ binding toward MA peptides. Number 
codes represent different MA peptides used in the experiments. Figure represents data from one of the 
three dilutions used and results from three independent experiments.  
 
Data showed that NAbs-Aβ recognize MA 02 and MA 04 better than the rest of the 
peptides compared (Figure 25). In agreement with the previous epitope 
characterization, addition of hydrophobic amino acid at the 33rd position of Aβ28-40, in 
this case t-leucine inclusion improved the NAbs-Aβ binding towards MA 04. The 
open-chained parallel dimers MA 02 stood as second best peptide recognized by 
NAbs-Aβ. Apart from these two, NAbs-Aβ binding was moderate towards the Aβ28-40 
sequence containing MA 03 (Aβ28-40) and MA 06. The peptide sequences that lack 
lysine at 28th position of Aβ showed relatively lower binding except MA 10. MA 
peptides with dimer inducing conformations MA 07, 08 and 09 showed poor binding.  
Interestingly, anti-parallel, dimeric closed ring structures MA 06 and MA 10 showed 
improved binding. In contrast, MA 07, the precursor (during peptide synthesis) of MA 
10 and has open N and C terminal ends (open ring) showed poor binding (Figure 25).  
In summary, results indicated that lysine-containing click peptides and peptides with 
fixed dimeric alignment were bound efficiently by NAbs-Aβ. .  
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3.3.1.2 Lysine at 28th position is crucial for NAbs-Aβ binding 
Further, truncated Aβ sequences displaying the epitope region (Ile 32) and anti-parallel 
dimer alignment of the epitope region were synthesized. MA peptide 13 was 
synthesized exhibiting the epitope region as a short-peptide of 5 amino acids length. 
MA 14 with same sequence as MA 13 with an additional click peptide 11-Azido-
tetraethylenglycol-1-acetid acid (Ata) was synthesized. MA 15, an anti-parallel closed-
ring structure with the same sequence as 13 was included in the experiment. Aβ 
truncated sequence between glycine 29 to isoleucine 32 with an additional isoleucine 
at position 33 was also included. Aβ sequence running from alanine 30 to glycine 38 
with an additional Azp at the N-terminal end was included to induce further 
oligomerization. MA 18, 19 and 20 with Aβ28-40 with N-terminal Spe, C-terminal Ata 
and N-terminal Spe along with C-terminal Ata, respectively, which improves 
oligomerization were included (Figure 26). The binding efficiency of NAbs-Aβ 
toward the MA peptides 13-20 was compared. Data showed that the peptides lacking 
Lysine at 28th position of Aβ were not bound by the NAbs-Aβ despite the anti-parallel 
dimer conformation (Figure 27). This data supports the previous observation with 
truncated peptides (Figure 10) where lack of Lys28 reduced the binding ability of 
NAbs-Aβ. On the other hand, MA 20 with both N-terminal Spe and C-terminal Ata 
improved the NAbs-Aβ binding. The results suggested that the short sequences with 5 
amino acids including the epitope region (isoleucine 32) was not enough to be bound 
by NAbs-Aβ. Addition of oligomerization inducing click peptides or the anti-parallel 
alignment did not help NAbs-Aβ binding. 
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Figure 26 Chemistry of MA peptides 13-20 
 
 
Figure 27 Comparison of MA 13 to 20 towards affinity purified NAbs. Bars represent OD at 450 
nm. Number codes represent different MA peptides used in the experiments. Figure represents data 
from one of the three dilutions used and with three consistent repeats showing similar results from three 
independent experiments.  
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3.3.1.3 Comparison of NAbs-Aβ binding to promising conformations 
of MA peptides 
Three promising candidates from each of the initial two experiments (MA 02, 04, 06, 
18, 19 and 20) were chosen and compared with the MA peptides 21 to 24 to study 
NAbs-Aβ binding. Additionally, wt Aβ1-40 and Aβ1-42 were included as positive 
controls. 
 
 
Figure 28 Comparison of best of MA 01to 20, Aβ1-40 and Aβ1-42 towards affinity purified NAbs. 
Bars represent OD at 450 nm. Figure represents data from one of the three dilutions used and with three 
consistent repeats showing similar results from three independent experiments.  
 
MA 21 exhibit Aβ29-33 with N-terminal trizol linked Spe (alkine) with α-Azido-Ribose 
(azide). MA 22 with same sequence as MA 21 with additional C-terminal Ata. MA 23 
was designed as closed anti-parallel dimers with click peptide 6-Azido-L-norleucine 
(Aln) sandwiched between Aβ24-27 and glycine 29. MA 24 to 27 had the same 
sqequence Aβ28-40 sequence Spe at the N-terminal and Azp at the C-terminal end 
forming a ring structure. MA 24-27 differs only in terms of the peptide purity during 
the preparation (Figure 29).  
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Figure 29 Chemistry of MA peptides 21 to 27 
The data demonstrated that MA 06 displaying the epitope sequence with flexible anti-
parallel dimeric conformation was recognized by NAbs-Aβ as good as Aβ1-42 (Figure 
28). MA 24 which exhibit a cyclic structure, MA 02 that has a flexible parallel dimeric 
conformation and MA 4, a truncated peptide of sequence 28-40 with G33Tle (L-tert-
Leucine) mutation were recognized better by NAbs-Aβ next to the above mentioned 
peptides. Fitting to the previous observations, among the positive controls, NAbs-Aβ 
recognize Aβ1-42 better than Aβ1-40. Cyclic conformation that represent truncated 
epitope region between Glycine 29 to Glycine 33 MA 21 and MA 22 were not 
exhibiting the epitope conformation bound by NAbs-Aβ despite having the epitope 
region and cyclic conformation as MA 24. MA 18-20 having 28-40 linear sequence 
had less binding due to the addition of 11-Azido tetraethylenglycol (AEG4) in MA 18, 
11-Azido-tetraethylenglycol-1-acetid acid (Ata) in MA 19 or L-Serine propargyl ether 
(Spe) in MA 20. 
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3.3.1.4 Comparison of C-terminal specific antibodies binding to 
promising conformations of MA peptides 
 
To make sure that NAbs-Aβ binding towards the peptides is specific and not because 
of any unspecific molecular crowding effect, Aβ specific monoclonal antibodies were 
tested as follows. Click peptides used in the previous experiment (3.3.1.3) were tested 
with C-terminal specific 5C3 and mid-terminal specific 4G8 monoclonal antibodies. 
The monoclonal antibody 5C3 was chosen due to its unique ability to bind exclusively 
to C-terminal end of Aβ1-40 but not towards Aβ1-42. Additionally, mid-terminal 
antibody (4G8) was used as a negative control in the experiment. MA peptides possess 
the C-terminal sequence of Aβ  and lack the mid-terminal domain toward which 4G8 
antibodies are directed at. As a positive control to the full length sequence of Aβ1-40 
and Aβ1-42 were included in the experiment. 
 
Figure 30 Comparison of best of MA 01to 24, Aβ1-40 and Aβ1-42 towards NAbs. C-terminal Aβ1-40 
specific monoclonal antibody 5C3 and mid-terminal specific m266 were used to probe the plates coated 
with different peptides. Number codes represent different MA peptides used in the experiments. Bars 
represent OD at 450 nm, bars in grey and black represent signal obtained due to binding towards 
peptides using 5C3 and 4G8, respectively. Figure represents data from one of the three dilutions (1:5000 
among 1:2500, 1:5000 and 1:10000) with 5C3 and one dilution with 4G8 (1:5000) and four independent 
experiments.  
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The results showed the specificity of the 5C3 antibodies binding towards Aβ1-40 or 
truncated forms with unaffected C-terminal domain MA 18 and with least binding 
towards Aβ1-42 and other MA peptides.  
 
The mid-terminal specific 4G8 antibodies detected full length Aβ1-40  and Aβ1-42 with 
intact mid-terminal sequence. In contrary, 4G8 does not bind any of the C-terminal 
domains of Aβ1-40 that lacks mid-terminal domain. 
 
3.3.1.5 NAbs-Aβ specifically recognize anti-parallel dimers 
In order to precisely find out the conformation of Aβ NAbs-Aβ recognize, as a final 
comparison, the most promising candidates among the previously compared peptides 
was studied. Additionally, MA 12 peptide which also displays anti-parallel dimeric 
structure, and the positive controls Aβ1-40 and Aβ1-42 were included. 
 
Figure 31 NAbs-Aβ recognize anti-parallel flexible dimeric structure of C-terminus of Aβ . 
Comparison of best of MA 1 to 25, MA 27, Aβ1-40 and Aβ1-42 towards affinity purified NAbs. Number 
codes represent different MA peptides used in the experiments. Bars represent OD at 450 nm. Figure 
represents data from one of the three dilutions used and three independent experiments.  
 
Compared to the other promising candidates tested in our previous experiments, 
NAbs-Aβ binding towards MA 6 remained the best (Figure 31), closely followed by 
MA 02 and MA 04. To some extent MA 03 and MA 25 were also displaying good 
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signals indicating NAbs-Aβ interaction. Aβ1-40 and Aβ1-42 showed similar pattern 
falling in line with our previous observations. MA 12 despite its anti-parallel dimeric 
structure did not provide a convincing signal, showing NAbs-Aβ recognize flexible 
anti-parallel dimers.  
 
 
Figure 32 Comparison of best of MA 01to 25, MA 27, Aβ1-40 and Aβ1-42 towards Aβ1-40 C-terminal 
specific 5C3 monoclonal antibodies. Number codes represent different MA peptides used in the 
experiments. Bars represent OD at 450 nm. Figure represents data from one of the three dilutions used 
and with four consistent repeats showing similar results from three independent experiments.  
As a control, the same set of peptides was used to study the binding of C-terminal 
specific 5C3 antibodies. The data showed 5C3 antibodies’ specificity towards Aβ1-40 
and MA 03 which is truncated form of C-terminal sequence 28-40. 
In summary, NAbs-Aβ binds to anti-parallel dimers and lysine residue at position 28 
helps its binding. Despite the inclusion of anti-parallel structure or the epitope region 
(isoleucine 32), the results demonstrate that the NAbs-Aβ binding is highly dependent 
on the anti-parallel structure including the lysine 28. 
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3.4 Characterization of C-terminal substitution mutant (Aβ1-
40;G29,33I)  
Epitope characterization studies revealed isoleucine substitution of at Aβ positions 29 
and 33 improved NAbs-Aβ binding (Figure 14). Further experiments showed the 
preferential binding of NAbs-Aβ toward oligomers of Aβ. In this regard, the double 
mutant Aβ1-40;G29,33I were tested for their oligomerization properties, secondary 
structures and cytotoxicity in the following sub-chapters.  
3.4.1 Double mutations at the C-terminal end instantly forms SDS-
stable oligomers   
To study the oligomerization characteristics of the mutation at the particular sites, 
freshly dissolved peptides were analyzed using SDS-PAGE. In addition to Aβ1-
42;G29,33I, two more full length Aβ1-42 peptide sequences, Aβ1-42;G29,33I and Aβ1-
42;G29,33I;A41I, were included in the experiment. Aβ1-42 were chosen due to its highly 
hydrophobic C-terminal sequence which tend to trigger oligomerization. 
 
 
Figure 33 Oligomerization of Aβ  due to isoleucine substitution. Silver stained SDS-PAGE show 
freshly dissolved mutant Aβ instantly form oligomers. Lanes 1, 2 and 3 were loaded with freshly 
resuspended Aβ mutants Aβ1-42;G29,33I, Aβ1-42;G29,33I  and Aβ1-42;G29,33I;A41I, respectively. 
 
Silver-stained SDS-PAGE results of mutant peptides Aβ1-40;G29,33Ile, Aβ1-42;G29,33Ile and 
Aβ1-42;G29,33Ile&A42Ile shows different pattern of oligomerization state. The double 
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mutation at positions 29 and 33 on Aβ1-40, form trimers and tetramers and less higher 
aggregates. On the contrary, Aβ1-42 with the same mutation form higher aggregates in 
addition to trimers and tetramers. Aβ1-42 with triple isoleucine substitution at positions 
29, 33 and 41 form similar pattern like Aβ1-42;G29,33I.  
 
Figure 34 Comparison of NAbs-Aβ binding towards monomers, dimers and trimers. Indirect 
ELISA, monomeric Aβ1-40, dimeric oligomerized Cys-Aβ1-40 and trimeric Aβ1-40;G29,31I were coated with 
0.1M Sodium Carbonate buffer. Affinity NAbs-Aβ (1mg/mL) were diluted with 1XPBS to 1: 3000 with 
quadruplicates. Bars represent the optical density measured at 450 nm after the treatment with HRP 
labelled goat-anti-human secondary antibodies followed by addition of TMB substrate. Figure 
represents the one of the dilutions among 4 dilutions with consistent pattern in three independent 
experiments. 
 
3.4.2 Double mutation at the GxxxG region decreases the cytotoxicity 
of the peptide 
The double mutation at GxxxG region of Aβ1-40;G29,33I (G29xxxG33 to I29xxxI33) 
forms instant SDS-stable trimers (Figure 33). Aβ peptide has been shown to be toxic 
to the neuronal cells. As Aβ1-40;G29,33I mutant forms instant trimers, its secondary 
structure, size and conformation of this mutant peptide might also differ from WT Aβ. 
In this regard further experiments were conducted to analyze the cytotoxicity of Aβ 
mutants. To study the toxicity, murine microglial and neuronal cells were treated with 
Aβ1-40;G29,33I mutant and WT Aβ1-40 and Aβ1-42, subsquently MTT assay was performed 
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for cell viability. Two different concentrations and different oligomerization states of 
peptides were used for the toxicity studies. In addition, a non-steroidal anti-
inflammatory drug, CNI-1493, which was previously reported to influence in Aβ 
oligomerization and improves cognition in transgenic animals were also included in 
the studies (Bacher et al., 2008).  
The cytotoxicity assays results from WT peptides were published by Dr. Bach et al 
(Bach et al.). The results shown here are repetition of the similar experimental 
parameters in addition to mutant peptides. I would like to thank Mr. David Megel for 
the support he offered by providing the protocol and the cell lines.  
 
3.4.2.1 Monomerized peptides (wild type and mutants) show no 
neurotoxicity  
Murine neuronal cells were treated with 1 or 5 µM of HFIP-pre-treated WT Aβ1-40 and 
Aβ1-42 peptides. HFIP treatment breaks down the oligomers into monomers by 
disrupting the tertiary structures (Kayed et al., 2003). Neuronal cell lines were 
preferred over the primary neurons as they are easy to cultivate. Additionally, CNI-
1493 was included to study the restoration of cell viability exerted by Aβ toxicity. 
 
Figure 35 Neurotoxicity of monomerized WT Aβ1-40 and Aβ1-42; and the role of CNI-1493 in 
preventing the toxic effect. Murine neuronal cell line N2A were treated for 48 hours with 1 and 5 µM 
of HFIP-pre-treated Aβ1-40 and Aβ1-42 which will contain more monomers due to HFIP pretreatment. 
Optical density corresponding to the MTT level of the untreated cells was set as 100% and percentage 
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of the cell survival of the Aβ treated was calculated. Bars represent percentage of cell survival after the 
peptide treatment. The data are representative of duplicated samples and one of three experiments. 
 
Data shows that the treatment of Aβ1-40 or Aβ1-42 freshly suspended peptides showed 
minimal toxicity with a maximum of approximately 20% toxicity with Aβ1-40 WT at 5 
µM concentration when compared to the untreated cells (Figure 35). These results are 
in line with previous reports where monomeric Aβ showed no neurotoxicity (Kayed et 
al., 2003).Whereas, CNI-1493 influence on cell survival is also found to be meager. 
 
 
Figure 36 Neurotoxicity of mutants Aβ1-40;G29,33I and Aβ1-42;G29,33I. N2A were treated with 1 and 5 
µM concentration of freshly prepared Aβ1-40 and Aβ1-42 monomers for 48 hours. Bars represent 
percentage of cell survival after peptide treatment. The data are representative of duplicated samples 
and one of three experiments.  
On the other hand, treatment of Aβ1-40;G29,33Ile and Aβ1-42;G29,33Ile freshly suspended 
peptides showed very less toxicity (Figure 36). This toxicity exerted by mutant 
peptides are comparitively weaker than the wild type peptides (Figure 35). The effect 
of CNI-1493 was found to be minimal due to the less toxicity driven by the mutant 
Aβ.  
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3.4.2.2  Monomerized Aβ peptides (wild type and mutants) show no 
toxicity on BV-2 cells  
Further, the Aβ toxicity on microglial cells was determined by the treatment of freshly 
prepared (monomerized) WT Aβ1-40 and Aβ1-42 of concentrations 1 and 5 µM. Similar 
to the N2A Aβ treatment, CNI-1493 treatment was also included in the experiment 
 
Figure 37 The cytotoxic effect of monomerized Aβ1-40 and Aβ1-42; and the role of CNI-1493 in 
microglial cell line (BV-2). Murine microglial cells (BV-2) were treated with freshly prepared HFIP 
pre-treated Aβ1-40 and Aβ1-42 monomers. Bars represent percentage of cell survival after peptide 
treatment, where OD corresponding to the untreated cells were taken as 100% cell survival. The data are 
representative of duplicated samples and one of three independent experiments. 
 
Treatment of monomerized Aβ1-40 and Aβ1-42 on microglial cell line showed moderate 
toxicity. Maximal toxicity of 27% was found in cells treated with WT Aβ1-42 at 5 µM 
concentration (Figure 37). CNI-1493 showed no beneficial effect in improving cell 
survival but shown a little toxicity, which is a negligible percentage.  
 
 
   RESULTS 
 
   68 
 
Figure 38 The cytotoxicity effect of mutants Aβ1-40;G29,33I and Aβ1-42;G29,33I. Murine microglial cells 
were treated with 1 and 5 µM concentration of HFIP pre-treated mutant peptides Aβ1-40;G29,33I and Aβ1-
42;G29,33I . Bars represent percentage of cell survival after peptide treatment, where OD value of untreated 
cells were taken as 100% cell survival. The data are representative of duplicated samples and one of 
three experiments. 
 
Mutant peptide treatment did not affect the BV-2 cell survival except 5 µM Aβ1-
42;G29,33I, which showed approximately 26% toxic, compared to the untreated cells. 
CNI-1493 showed no beneficial effect on peptide treated with Aβ mutants (Figure 38).  
3.4.2.3 Wild type Oligomers are toxic on N2A cells, and CNI-1493 
facilitates the cell survival 
It was previously shown that synthetic Aβ oligomers have neurotoxic effect (Kayed et 
al., 2003). The same Aβ oligomerization protocol was used to study the cytotoxic 
effect of WT and mutated Aβ. In addition to the peptides, subsequently after Aβ 
oligomers preparation peptides were co-incubated for 20 mins with CNI-1493. Similar 
to the previous experiments, neuronal cell line N2A was used to perform the MTT cell 
viability assay.  
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Figure 39 Neurotoxicity of oligomers of wild type Aβ1-40 and Aβ1-42; and the rescuing effect CNI-
1493. N2A were treated with oligomers of WT Aβ1-40 and Aβ1-42. Bars represent percentage of cell 
survival after peptide treatment where OD of untreated cells were taken as 100%. The data are 
representative of duplicated samples and one of three experiments.  
 
In contrary to monomerized Aβ, treatment of oligomerized both Aβ1-40 and Aβ1-42 
peptides showed toxicity on neuronal cell lines. Oligomers of Aβ1-40 showed 
approximately 35 to 38% toxicity at 1 and 5 µM concentrations respectively. 
Concentrations were calculated according to the amount monomers of Aβ, as the exact 
proportion of Aβ species could not be accurately estimated due to its high aggregation 
rate. Oligomeric species of Aβ1-42 exerted more toxicity on neuronal cells compared 
the Aβ1-40 oligomers. 1 µM Aβ1-42 oligomers induced approximately 27% of cell death 
and remarkably 5 µM triggered 54% toxicity (Figure 39).  
 
CNI-1493 treatment improved the cell survival from both Aβ1-40 and Aβ1-42 induced 
toxicity. The treatment showed notable improvement in cell survival from olgomeric 
Aβ1-42 induced toxicity. 
 
3.4.2.4  Oligomers of mutant peptides are non-toxic to N2A cells 
Treatment of wt Aβ oligomers showed to be toxcit to the neuronal cells (Figure 39). 
To determine the toxicity of mutant Aβ peptide, Aβ1-40;G29,33I and Aβ1-42;G29,33I were 
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separately incubated under the same oligomerization conditions as the previous 
experiment (3.4.2.3). 
 
Figure 40 The Neurotoxicity of oligomers of mutant Aβ1-40;G29,33I and Aβ1-42;G29,33I and the role of 
CNI-1493 in preventing the toxic effect. N2A were treated with Aβ1-40;G29,33I and Aβ1-42;G29,33I pre-
incubated under oligomer inducing conditions. OD obtained with untreated cells were set as 100% cell 
survival. Bars represent percentage of cell survival calculated with OD of untreated cell survival as 
100%. The data are representative of duplicated samples and one of three experiments.  
 
In this approach, oligomers of Aβ1-40;G29,33I and Aβ1-42;G29,33I did not show as much 
toxicity as WT oligomers. 1 and 5 µM Aβ1-40;G29,33I exerted 14 and 25 %, respectively. 
Whereas, 1 µM of Aβ1-42;G29,33I oligomers showed 24% toxicity in contrary 5 µM of 
Aβ1-42;G29,33I oligomers showed only 16% (Figure 40). These data suggests that either 
the mutated Aβ peptides does not form toxic oligomers under the oligomerization 
condition as WT Aβ does, or oligomers of mutated Aβ are non-toxic. Addition of CNI-
1493 shows no remarkable difference in recovering the little toxicity induced by 
mutant peptides. 
 
3.4.2.5 Wild type Oligomers are toxic on BV-2 cells and CNI-1493 
minimizes the toxicity 
Similar experiments were performed on BV-2 cells using the oligomers prepared for 
the N2A cells treatment. WT Aβ oligomers were incubated either with or without 
CNI-1493 pre-incubation.  
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Figure 41 The cytotoxic effect of oligomers derived from wild type Aβ1-40 and Aβ1-42; and the 
protective role of CNI-1493 on microglial cell survival. BV-2 cells were treated for 48 hours with 
oligomers of wild type Aβ1-40 and Aβ1-42. Prior to treatment on cells the peptides were maintained under 
conditions which trigger oligomerization. OD values of untreated cells were taken as the 100% surival. 
Bars represent percentage of cell survival after peptide treatment. The data are representative of 
duplicated samples and one of three experiments. 
 
Similar to the effect on neuronal cell lines (Figure 39), treatment of oligomerized Aβ1-
40 and Aβ1-42 peptides showed toxicity on microglial cell lines (Figure 41). Treatment 
of oligomerized Aβ1-40 at concentrations 1 and 5 µM showed a moderate toxicity of 19 
to 26%, respectively. Microglial cells treated with 1 µM Aβ1-42 oligomers induced 
21% of cell death and remarkably 5 µM triggered 53% toxicity on microglial cell line. 
CNI-1493 treatment improved the cell survival from both Aβ1-40 and Aβ1-42 induced 
toxicity. The CNI-1493 treatment showed an improvement of around 16% in cell 
survival against oligomeric Aβ1-42 induced toxicity. These results indicate that CNI-
1493 has beneficial effect against Aβ toxicity on both neuronal (Figure 39) and 
microglial cells (Figure 41). 
 
3.4.2.6 Oligomers of mutant peptides are non-toxic BV-2 cells, and 
CNI-1493 increases the toxicity 
Further, the effect of mutant Aβ incubated under oligomerization condition on 
microglial cells was studied. Aβ1-40;G29,33I and Aβ1-42;G29,33I incubated in an oligomer 
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inducing condition coupled with or without CNI-1493 co-incubation were fed to the 
microglial cells. 
 
Figure 42 The cytotoxicity of oligomers of mutant Aβ1-40;G29,33I and Aβ1-42;G29,33I and the role of 
CNI-1493 treatment. Murine neuronal cells (BV-2) were treated with oligomers of Aβ1-40;G29,33I and 
Aβ1-42;G29,33I. Prior to treatment on cells the peptides were maintained under inducing conditions with or 
without CNI-1493. Untreated cells were taken as positive control with 100% cell survival. Bars 
represent percentage of cell survival after peptide treatment. The data are representative of duplicated 
samples and one of three experiments.  
 
Treatment of peptides incubated in oligomerization condition on microglial cells 
showed moderate toxicity. Aβ1-40;G29,33I and Aβ1-42;G29,33I either undergone 
monomerizing or oligomerizing treatment did not display any cytotoxic effects on 
microglial cells. The maximum toxicity exererted by 5 µM Aβ1-40;G29,33Ile  was around 
23% (Figure 42). 5 µM concentration of Aβ1-42 double mutant showed even lesser 
toxicity of only 10 % cell death. On the contrary, addition of CNI-1493 showed 14% 
and 28% more toxicity than with the cells treated with Aβ1-40;G29,33I and Aβ1-42;G29,33I 
alone. 
 
In summary, monomerized WT Aβ1-40 and Aβ1-42 or mutated Aβ1-40;G29,33I and Aβ1-
42;G29,33I did not show any remarkable toxicity on both neuronal and microglial cells. 
Co-incubation of monomerized Aβ peptides with CNI-1493 did not offer any 
beneficial effect. WT Aβ1-40 and Aβ1-42 incubated under oligomerization inducing 
condition exerted a noticeable cytotoxicity on neuronal and microglial cell lines. CNI-
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1493 restored the cell survival against the WT Aβ oligomers induced cyotoxocity in 
both cell types. Mutated Aβ1-40;G29,33I and Aβ1-42;G29,33I did not show any toxicity in 
both monomerized or incubated in an oligomer inducing condition on any of the cell 
type. On the contrary, microglial cells treated with mutant Aβ peptides co-incubated 
with CNI-193 in an oligomer inducing condition showed a moderate cytotoxicity. 
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3.5 Comparison of amyloid beta specific antibodies to NAbs-Aβ 
Built around Aβ hypothesis, there are clinical trials involving Aβ immunotherapy for 
AD. Aβ form several intermediates between monomers to fibrils. While targeting the 
Aβ it is crucial to know the toxic species, as Aβ is important for normal synaptic 
functions. Recent evidences suggest that Aβ oligomers are causative agents of Aβ, 
hence, targeting Aβ oligomers are expected to improve the rate of success in AD 
therapy. In this regard, this study was planned to study the antibodies that are currently 
in clinical trial to understand their binding properties toward Aβ oligomers. In the 
previous chapters, a mutant Aβ oligomer that stabilizes a trimeric conformationally 
distinct Aβ (3.4.1) and a stabilized dimers using cysteine were characterized (3.2.1). 
The monoclonal antibodies currently undergoing clinical trials and NAbs-Aβ were 
compared for their binding toward different oligomeric species of Aβ. In the first 
experiment, binding ability of N-terminal specific murine 3D6 antibodies (Schenk et 
al., 1999), oligomer specific rabbit A11 antibodies (Kayed et al., 2003) were compared 
with NAbs-Aβ. In the second experiment, the anti-fibrillation properties of m266 and 
NAbs-Aβ were tested. 3D6 and A11 antibodies were omitted for the experiments due 
to their N-terminal specificity that might not influence fibrillation and lack of enough 
quantity to perform the experiments, respectively.  
 
3.5.1  Comparison of monoclonal antibodies and NAbs-Aβ for Aβ 
oligomer binding  
Antibodies currently in the passive immunotherapy clinical trials are designed to target 
Aβ. Since the concept of Aβ oligomers was relatively new, and due to lack of stable 
oligomeric Aβ preparation strategies most of the antibodies in the clinical trial are 
conformationally unspecific. In this regard, N-terminal specific, conformationally 
unspecific 3D6, conformational specific A11 antibodies were compared with NAbs-
Aβ. In this study, monomerized WT Aβ1-40 and Aβ1-42, N-terminal cysteine added 
dimer enriched cys-Aβ1-40 (3.2.1) and trimeric Aβ1-40;G29,33I (3.4.1) were 
immunoprecipitated with the antibodies.  
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Figure 43 Immunoprecipitation of different Aβ  species with NAbs-Aβ, A11 and 3D6 antibodies. 
Synthetic Aβ peptides in different states of oligomerization were immunoprecipitated using affinity 
purified NAbs-Aβ, oligomer specific A11 and N-terminal specific 3D6 antibodies. Immunoprecipitates 
were separated by 10-20% gradient tricine SDS-PAGE. Immunoblots were probed using 
immunoblotting with two antibodies 6E10 and 4G8, N-terminal and mid-terminal specific antibodies, 
respectively. 4 peptide preparations immunoprecipitated were: WT Aβ1-40, dimer enriched N-terminally 
cysteine tagged Aβ1-40, double mutant which forms trimers Aβ1-40;G29,33I and WT Aβ1-42. Panel I, II and 
III represents immunoprecipitates of NAbs-Aβ, A11 and 3D6 antibodies, respectively. 
 
Immunoprecipitation experiments (Panel I) indicated that NAbs-Aβ do not recognize 
monomeric Aβ1-40, but could interact to enriched dimers Aβcys1-40, trimeric Aβ1-
40;G29,33I and wild type Aβ1-42. Results demonstarated that A11 (Panel II) less binding to 
most of the peptides used. Similar to NAbs-Aβ, A11 does not bind to monomeric Aβ1-
40 and moderate binding toward Aβ1-42. Interestingly, there was low binding towards 
Aβ1-40;G29,33I mutant peptides, but not to the SDS-stable trimeric Aβ1-40;G29,33I. Binding 
of A11 towards the cysteine containing dimer enriched Aβcys1-40 and WT Aβ1-42 were 
better than with other peptides. 3D6 antibodies bind to most all the species of Aβ, 
including the oligomers of Aβ1-40;G29,33I. The binding of 3D6 toward dimer enriched 
Aβcys1-40 was found to be affected completely due to the N-terminal cysteine (Figure 
43). These results suggested that NAbs-Aβ binding toward the Aβ1-40;G29,33I is not due 
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to molecular clouding as A11 does not bind to the trimeric species of Aβ. 3D6 
demonstrated high specificity toward the N-terminal sequence, incorportation of one 
additional amino acid completely abolishes the binding. Oligomer specific A11 
antibodies showed their specificity toward the oligomeric specific of Aβ. Interestingly, 
A11 does not recognize the SDS-stable Aβ1-40;G29,33I but does bind to the SDS-instable 
Aβ1-40;G29,33I. 
3.5.2  NAbs-Aβ prevents fibrillation efficiently compared to m266 
To investigation whether NAbs-Aβ could prevent Aβ aggregation, Aβ fibrillation 
assay was conducted. As there are no widely accepted methods to study the 
oligomerization, fibrillation assay was used in this regard. NAbs-Aβ, which is C-
terminal sequence, and mid-terminus specific m266, were tested for their anti-
fibrillation properties. 15 µM antibodies were co-incubated with Aβ to study their 
efficiency to prevent Aβ fibrillation. Aβ1-40 was used as positive control and taken as 
100% value.  
 
Figure 44 Fibrillation assay: NAbs-Aβ prevents Aβ1-40 fibrillation. Aβ1-40 was incubated with or 
without antibodies for 48 hours in a fibrillation favouring condition. Fibrillation of Aβ1-40 was taken as 
100% and fibrillation in the presence of antibodies were calculated accordingly. The bars represent the 
percentage of Aβ fibrillation. 
 
The data suggests that NAbs-Aβ could efficiently slow down the fibrillation compared to m266 (Figure 
44). Compared to the Aβ alone m266 could restrict the fibirllation to 62 % NAbs-Aβ could efficiently 
supress the fibirllation of Aβ to 25%. This effectively anti-fibrillation property of NAbs-Aβ could be 
due to its binding specificity toward the C-terminal end of Aβ. 
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3.6 Effect of an anti-inflammatory (CNI-1493) drug on Aβ  oligomers 
Alzheimer’s disease is a neuro-inflammatory disease and many groups have reported 
the influence of cytokines in disease progression of this disease. There was more than 
one clinical trial in which anti-inflammatory drugs had been used for the treatment of 
Alzheimer’s disease. CNI-1493 that is already in clinical phase II research for Corn’s 
disease has MAP-kinase inhibitory action. Previous studies in our laboratory 
demonstrated that CNI-1493 decreases the plaque deposition and improves cognition 
in transgenic animals mimicking Alzheimer’s disease (Bacher et al., 2008). Previously 
results supported that the CNI-1493 treatment could exert a protective effect against 
Aβ oligomer induced toxicity on both neuronal (3.4.2.3) and microglial cell lines 
(3.4.2.5). In this study, biochemical experiments were conducted to investigate the role 
of CNI-1493 on oligomers.   
3.6.1 CNI-1493 binds to amyloid beta oligomers and breaks them 
into smaller forms 
CNI-1493 showed a scavenger effect on both neuronal and microglial cells treated 
with Aβ oligomers (Figure 39), (Figure 41). To explore the effect of CNI-1493 on Aβ 
oligomers, biochemical experiments were performed. Immunoblot and dot blot 
experiments were conducted on samples, where the CNI-1493 along with Aβ 
oligomers was co-incubated. Addition of CNI-1493 instantly precipitated Aβ which 
was visible to the naked eye (Data not shown).  
To study the effect of CNI-1493 on the oligomeric Aβ, WT Aβ1-42 and Aβ1-42;G29,33I;A41I 
which forms instant oligomers were co-incubated with or without CNI-1493. Samples 
were immunobloted and probed with N-terminal specific 3D6 and mid-terminal 
specific 4G8 antibodies. 
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Figure 45 Immunoblot: showing incubation with CNI-1493 breaks the SDS-stable oligomers to 
yield increased monomer ratio in the treated samples. Oligomers prepared with Aβ1-42 wild type and 
Aβ1-42;G29,33I;A41I  mutants were incubated with CNI-1493. The Samples were separated upon their 
molecular weight by SDS-PAGE gel electrophoresis under non-denaturing conditions using 10-20% 
tricine gel.The samples were transferred onto nitrocellulose membrane using Western blot and probed 
using N-terminal speicific 3D6 and mid-terminal specific 4G8 antibodies. In the figure, left panel shows 
the Aβ1-42 and the right panel displays the Aβ1-42;G29,33I;A41I  oligomers, incubated without or with CNI-
1493. 
 
The results demonstrated that the CNI-1493 could break down the SDS-stable 
oligomers to monomers (Figure 45). Immunoblotting the samples incubated without 
CNI-1493 showed less monomers compared to the treated. This effect was also found 
in Aβ1-42;G29,33I;A41I oligomers treated with CNI-1493, which improves the amount of 
broken down monomers from the SDS-stable oligomeric complex. 
 
 
3.6.2 CNI-1493 breaks toxic oligomeric conformation of Aβ 
Further, to prove the previous observation, dot blot experiment was conducted. The 
data provided here are exclusively performed by Mr. Roman Sankowski, Department 
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of Neurology, Philipps-University of Marburg. I would like to thank him for his 
gratitude to provide this results to add in my thesis. 
Aβ oligomers were co-incubated with different concentrations of CNI-1493 and dotted 
on nitrocellulose membrane. Blot was then probed using oligomer specific antibodies 
A11. A11 antibodies as mentioned earlier, recognize exclusively the toxic oligomeric 
conformation of the Aβ peptide (Kayed et al., 2003). The bound antibodies were 
removed using stripping procedure and reprobed with N-terminal specific 3D6 
antibodies. Stripping and reprobing of the membrane was performed as a positive 
control to check the presence of Aβ on the membrane. 
 
 
Figure 46 Dot blot demonstrating CNI-1493 affects the conformation of Aβ . Incubation of different 
concentrations of CNI-1493 shows a concentration dependent decrease in A11 detection (B, C and D), 
which was not found on the spots where Aβ oligomers were incubated in the solven alone (F, G and H). 
Stripping the blot and reprobing with N-terminal specific 3D6 antibodies could detect Aβ peptides 
dotted on the membrane. 
Dot blotting with A11 antibodies showed that CNI-1493 destabilizes the conformation 
of oligomerized Aβ peptides in a concentration dependant manner. The inability of 
A11 antibodies in the samples coincubated with CNI-1493 proves that the drug could 
break down the oligomeric conformation of Aβ. Stripping the membrane and 
reprobing with N-terminal specific 3D6 antibodies was used as a positive loading 
control. Probing with 3D6 showed the presence of Aβ peptide. As a negative control 
samples treated with the solvent alone did not affect the binding of both A11 and 3D6 
antibodies (Figure 46).  
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4 DISCUSSION 
It is its ‘nature’ to cause diseases, as it is the immune system’s ‘nature’ to ‘defend the 
body’. Naturally occurring autoantibodies (NAbs) are one such precious gift of nature 
given to us for our well-being. Previously, we have shown that NAbs contain 
antibodies against Aβ (Balakrishnan et al., 2010; Dodel et al., 2011; Dodel et al., 
2004). Excessive accumulation of misfolded Aβ peptide is one of the main culprits to 
cause AD. The physiological role of Aβ peptide remains unclear. Aβ, within 
physiological levels, are essential to perform normal synaptic activities in the brain. 
Apart from the overproduction of Aβ observed in the familial (early onset) AD 
patients carrying mutated APP (Chartier-Harlin et al., 1991; Citron et al., 1992; Goate 
et al., 1991), impaired clearance of normally produced Aβ leads to Aβ accumulation. 
Decreased levels of Aβ specific autoantibodies in AD patients (Weksler et al., 2002) 
may therefore lead to Aβ accumulation and are suspected to be one of the causative 
features of AD (Dodel et al., 2009). On the contrary, some reports suggest that the 
autoantibodies are increased (Moir et al., 2005; Nath et al., 2003) in AD patients  
 
Apart from the currently available therapies (1.5.1), which offer symptomatic reliefs, 
there are two disease-modifying approaches to treat AD with respect to amyloid 
hypothesis. 1. Drugs targeting Aβ production by regulating/inhibiting β or  γ-secretase. 
But recently AD therapeutic research faced a major setback against the  γ-secretase 
inhibiting drug therapy. The γ-secretase inhibitory effect of the drug worsened the 
cognitive function of patients treated compared to the placebo treated control group 
(Extance; Lilly, 2010). 2. Vaccination approach to clear Aβ from the brain (1.5.2).  
 
Considering the complexity of Aβ aggregation and role of its conformation in disease, 
the choice of antibodies becomes crucial. Antibodies recognizing monomeric Aβ 
peptide sequence does not necessarily become an ideal candidate for passive 
immunotherapy. Using monoclonal antibodies targeting physiological Aβ or APP 
products, like sAPPα may lead to adverse effect. As a potential alternative, 
conformation specific antibodies that could specifically target ‘toxic’ conformation of 
Aβ, but not towards other by-products of secretase cleavage may be an effective and 
safer approach. In this perspective, we proposed NAbs as a possible potential 
candidate for immunotherapy (Dodel et al., 2002). IVIGs are FDA approved 
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therapeutic agent to treat immunological disorders like autoimmunity and 
immunodeficiency. Additionally, there are evidences suggesting that NAbs recognize 
conformational epitopes on Aβ.  
 
In the first chapter of the discussion, I describe both the region and conformation 
epitope of Aβ recognized by NAbs-Aβ, and thereby suggesting why it is imperative to 
use NAbs-Aβ as a therapeutic agent. Characterization of a novel oligomeric species of 
Aβ raised by artificial double mutation on WT Aβ will be described in the second 
chapter. Final chapter describes the role of an anti-inflammatory drug on Aβ oligomers 
and regulation of secretase pathways involved in Alzheimer’s disease.  
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4.1 Presence of Aβ specific autoantibodies in IVIG  
Aim of the study is to investigate the Aβ epitope region recognized by NAbs-Aβ. 
Extraction of Aβ from AD brain showed different variants of post-translationally 
modified, oxidized and truncated Aβ (Iwatsubo et al., 1996; Mori et al., 1992; Naslund 
et al., 1994; Piccini et al., 2005). Similarly, human serum pool contains different 
antibodies which are used to treat immunological diseases also possess Aβ specific 
antibodies (Dodel et al., 2002). Less is known about the NAbs binding region on Aβ 
epitope.  
 
First of all, experiments were conducted to compare the levels of Aβ specific 
antibodies present in different commercial IVIG available in the market. The indirect 
ELISA results showed all of the IVIGs contain Aβ specific antibodies. Interestingly, 
some IVIG preparations had differing ratio of antibodies directed towards Aβ1-40 
(Figure 5) and Aβ1-42 (Figure 6). Among all the IVIG brands compared (Table 2), 
Octagam and Gammunex showed the strongest binding towards Aβ1-40 and Aβ1-42. 
Other brands Sandoglobulin, Gammagard and Intratect, but interestingly Kiovig had 
the lowest concentration of NAbs-Aβ specific to Aβ1-40 and showed moderate levels 
towards Aβ1-42. This observation reconfirms the existence of a variety of NAbs in 
IVIG and in turn serum pool, especially with N and/or C terminal domain specificity. 
These differences of NAbs among the different IVIG brands suggest that the 
production strategies and/or composition of storage buffers may influence the levels of 
Aβ specific NAbs. Although binding affinity towards Aβ is not directly proportional to 
efficacy of the IVIG, the amount of NAbs-Aβ should be considered before using in 
AD clinical trials (Balakrishnan et al., 2010).  
 
4.2 Characterization of Aβ epitope recognized by NAbs-Aβ 
Throughout the epitope characterization experiments NAbs-Aβ purified from IVIG 
brand Octagam, were used. Aβ domain specificity of NAbs-Aβ were determined 
coating different truncated domains of Aβ and tested using indirect ELISA. The 
comparison showed the C-terminal specific affinity of NAbs-Aβ. Next to the full 
length Aβ1-40, NAbs-Aβ showed better binding to the C-terminal (CT) end compared 
to the truncated peptides representing N-terminus, mid-terminus (Balakrishnan et al., 
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2010). Interestingly, the binding of NAbs-Aβ was less toward the truncated sequence 
20-38 (lacks Valine 39 & 40) despite its sequence similarity to 25-40 (Figure 7). This 
set of data emphasizes the importance of the last two amino acids (Valine 39 and 40) 
of Aβ1-40 for NAbs binding. Aβ1-38 is one of the three possible products out of γ-
secretase cleavage and relatively less neurotoxic when compared to the other two γ-
secretase products. This effect may be because of the hydrophobic Valine at 39 and 40 
that triggers oligomerization. In summary, this data provides two possible explanations 
for NAbs-Aβ binding (i) Valine at 39 and 40 represents the epitope region or (ii) the 
oligomerization induced by Valine thereby form certain oligomers that facilitates 
NAbs-Aβ binding. This finding strongly suggests that the NAbs-Aβ recognize the CT 
end of Aβ. Role of CT end in Aβ oligomerization hints that the NAbs-Aβ’s CT 
specificity may also be due to their binding ability towards oligomers. This 
observation further supports the previous reports suggesting that the human antibody 
pool consists of antibodies specific to both N and C-terminal end of Aβ. Human 
antibody pool or the purified IVIG contains N-terminal specific antibodies that are 
specific to fibrillar conformation and C-terminal sequence specific antibodies that are 
conformer specific (Balakrishnan et al., 2010; Britschgi et al., 2009; Dodel et al., 
2011; O'Nuallain et al., 2008). 
 
Further characterization using alanine-scanning mutagenesis showed that positions 25 
to 27 do not represent the Aβ epitope region. In principle, replacement of original 
amino acid with alanine abolishes binding of antibodies at that position; this is due to 
inert property of side chain that cannot act as an epitope. Additionally, exchange of L-
Serine to D-Serine at position 26 had no influence on binding of NAbs-Aβ. These data 
reflect that Glycine at 25, Serine at 26 or Asparagine at position 27 are not part of the 
Aβ epitope region (Figure 8). Based on these data the amino acid sequence between 
28-40 plays a crucial role for the NAbs-Aβ binding.  
 
Lysine at 28th position of Aβ compared to the other Aβ fragments improves the 
positive charge at physiological pH and was reported to be highly toxic due to the 
presence of Lys28 at the N-terminus (Fradinger et al., 2008). Additionally, Lys28 is 
possibly the key amino acid to collapse the cross-beta sheet structure (Numata and 
Kaplan, 2010). Taking these points into account 3 truncated peptides 26-42, 28-42, 
and 30-42 were compared for NAbs-Aβ binding. To avoid shortening of the length of 
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the truncated peptide the C-terminal end (x-42) was preferred instead of x-40 for the 
NAbs-binding studies. Results showed that NAbs-Aβ recognize Aβ28-42 better than 
Aβ1-40, in addition Aβ30-42 has decreased binding to NAbs-Aβ . The improved binding 
may be due to two reasons, either Lys28 is one of the amino acids representing a 
critical part of the epitope region that NAbs-Aβ recognize or it helps the solubility of 
the peptide at neutral pH and provides β-sheet conformation due to its positive charge 
as previously reported (Terzi et al., 1994). Decreased binding of Aβ30-42 towards 
NAbs-Aβ also supports the assumption that Aβ28-42 is the crucial epitope region or 
poor solubility due to lack of the peptide and could therefore technically affect the 
ELISA to decrease the binding of NAbs-Aβ (Figure 10). Additionally, short truncated 
version of conformationally fixed peptides that lack Lys 28 were poorly bound by 
NAbs-Aβ, which will be discussed in detail in the following chapter (4.3). Aβ28-40 
consists of 4 glycine and one alanine residues which cannot act as epitope due to lack 
of the functional group. Taken together, these data shortlists about 3 to 6 amino acids 
in the CT end that could represent Aβ epitope region for NAbs-Aβ binding. 
Previously, Tycko and Petkova have developed a model using the information they 
obtained through the studies on Aβ40 residues. The model proposes that 9-24 and 30-
40 are parallel in-register β-sheets and 23-29 is the loop region stabilizing these β-
sheets (Petkova et al., 2002; Petkova et al., 2006) (Figure 47). NAbs-Aβ, which 
recognize between 28-40 sequences, with respect to the proposed Petkova model, 
binds to the one of the β-pleated conformation of Aβ. Interestingly, this sequence of 
amino acid is the membrane bound region of Aβ (Figure 48).  
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Figure 47 Petkova model (a) Schematic representation of a single molecular layer, or cross-β unit. The 
yellow arrow indicates the direction of the long axis of the fibril, which coincides with the direction of 
intermolecular backbone hydrogen bonds. The cross-β unit is a double-layered structure, with in-
register parallel β-sheets formed by residues 12–24 (orange ribbons) and 30–40 (blue ribbons). (b) 
Central Aβ1–40 molecule from the energy-minimized, five-chain system, viewed down the long axis of 
the fibril. Residues are color-coded according to their side chains as hydrophobic (green), polar 
(magenta), positive (blue), or negative (red).  
 
Methionine at position 35 could also possibly act as an epitope because it is the only 
sulphur containing proteinogenic amino acid present in Aβ1-42 sequence. Additionally, 
Methionine at 35th position is a critical amino acid for oxidative stress and neurotoxic 
properties of native Aβ peptides (Drake et al., 2003; Yatin et al., 1999). Alanine scan 
at 35th position did not affect the NAbs-Aβ binding (Figure 11). This indicates that the 
methionine is not representing the epitope region for NAbs-Aβ.  
Apart from methionine and glycine the remaining amino acids in this domain are 
hydrophobic and may raise the question whether NAbs-Aβ binding towards the Aβ 
peptide is an unspecific hydrophobic interaction. Interestingly, substitution of 
hydrophobic Alanine at Gly33 improved the binding signal indicating an increased 
NAbs-Aβ binding (Figure 11). Further, it has been reported that C-terminal domain of 
the Aβ peptide, due to its hydrophobic nature, is responsible for the oligomerization 
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(Jarrett et al., 1993; Numata and Kaplan, 2010). The improved binding of NAbs-Aβ 
towards mutated peptide, which we propose, is due to the property of NAbs-Aβ 
recognizing certain ‘oligomers’. This could be verified with the data where we could 
show that specific mutations at 29 and 33rd position forms an oligomeric structure of 
the Aβ peptide. The oligomerized structure of that Aβ peptide will be discussed in 
detail in the following chapter (4.5). In addition, the binding of NAbs-Aβ to the C-
terminus could inhibit the fibrillation compared to mid-terminal specific antibodies 
(Figure 44).  
 
The addition of N-terminal cysteine to Aβ1-40 improves the binding of NAbs-Aβ. But 
N-terminal cysteine addition does not influence Aβ1-12 binding (Figure 12). This 
indicates three properties of NAbs-Aβ:  
• The addition of cysteine helps in oligomerization (forming cystine disulphide 
bonds) and thereby improves the binding. 
• Despite the presence of cysteine, the poor binding ability of NAbs-Aβ to Aβ1-12 
show that their interaction was not with cysteine but specific to aggregates of C-
terminal Aβ. 
• This further clarifies the effect of the oligomerization that improves NAbs-Aβ 
biding to cys-Aβ1-40 better than towards wt Aβ1-40 (Figure 12, Figure 18 Figure 21).  
Interestingly, the weak binding partner Aβ20-38 could interact better with NAbs-Aβ by 
replacing valine with cysteine at 39th position. Aβ20-38 was poorly bound by NAbs-Aβ 
compared to Aβ25-40 despite having similar sequence except 39 and 40. This effect 
might be due to the lack of hydrophobic valine at positions 39 and 40, and thereby less 
oligomerization. This shows that 39 or 40th valine residues are not acting as epitope, 
but helps in oligomerization of the peptide. Alanine scans at three positions on Aβ28-42; 
Ileu31, Leu34 and Val40 shows no decline in the binding signal provided due to 
NAbs-Aβ interaction (Figure 12).  
 
Taken together, the Aβ epitope recognized by NAbs-Aβ lies between the sequence 28-
40. The moderate signal provided by NAbs-Aβ binding towards Aβ30-42 shows that 
lysine at 28 important and helps in stabilizing a structure and exposes the epitope 
region. Glycine present at positions 29, 33, 37 and 38 of Aβ and alanine at position 30 
cannot represent the epitope due to their lack of lateral side chains, which make them 
inert to interact with antibodies. Alanine scanning shows replacing Ileu31, Leu34, and 
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Met35 with alanine did not affect the interaction of NAbs towards Aβ (Figure 12). 
Substitution of cysteine with valine at 39th improves the binding revealing C-terminal 
valine residues are participating in oligomerization and not one of the epitope 
representing amino acids. According to the results we obtained, Lys28, Gly29, Ala30, 
Ile31, Gly33, Leu34, Met35, Gly37, Gly38, Val39 and Val40 are not representing the 
epitope region. This leaves behind Ile32 or Val36, if the NAbs-Aβ are specific to Aβ, 
alanine replacement at Ile32 or Val36 or both replaced should abolish the NAbs-Aβ 
binding.  
 
As expected, there was a remarkable decline in the NAbs-Aβ binding to Aβ28-42 with 
alanine substitutions at Ile32, Met35 and Val40 (Figure 14). Additionally, a scramble 
sequence (every amino acid except Ile32, Met35 and Val40 were replaced with amino 
acids of similar physical properties) showed similar NAbs-Aβ binding compared to the 
WT Aβ1-40 (Figure 14). These results clearly demonstrate the role of Ile32, Met35 and 
Val40 in representing the critical amino acids of the epitope region of NAbs-Aβ. 
 
Furthermore, the unaffected binding signal after exchanging Asp23 and Lys28 shows 
the loop formation proposed by Petkova et al does not play any crucial role in NAbs-
Aβ binding (Figure 14). According to the Petkova et al model, there lies two parallel 
β-sheet structures within the mid (12-24) and the C-terminal end (30-40) of Aβ peptide 
(Figure 47). This supports that the epitope region lies between 30-40 β-sheet structure. 
Cysteine addition at the C-terminal end moderately decreases the binding of NAbs-Aβ 
compared to cysteine added to the N terminal or to both ends of the peptide (Figure 
14).  
 
Alanine scan exclusively at Ile32 could completely abolish NAbs-Aβ binding (Figure 
15). This result nails down the epitope region. Either Ile32 alone or Ile32 in 
combination with other amino acids completely abolishes NAbs-Aβ binding (Figure 
15). We propose, either Ile32 represents the Aβ epitope, or Ile32 helps in the 
oligomerization of Aβ that effectively unravels the epitope region, for NAbs-Aβ 
binding. In support of the observation that the oligomerization of Aβ improves NAbs-
Aβ binding, a time course oligomerization experiments shows that NAbs-Aβ 
recognize particularly enriched form of dimers (Figure 18-Figure 21).  
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4.3 NAbs-Aβ binding towards conformationally fixed peptides  
Given the complexity of Aβ aggregation, conformationally fixed ‘‘click’’ peptides 
(that slows down the aggregation process) were used to identify the right conformation 
of NAbs-Aβ recognized Aβ epitope. Comparison studies of NAbs-Aβ to different 
monomeric and dimeric truncated Aβ species demonstrated clearly that NAbs-Aβ 
preferentially binds to Aβ oligomers. In line with the previous observation, out of 12 
conformationally fixed MA peptides, Gly33 replaced with hydrophobic t-leu, and 
Aβ28-40 with open flexible (MA 04) and closed (MA 06) dimeric conformation showed 
improved recognition by NAbs-Aβ (Figure 23-Figure 25). Conformationally fixed 
peptides re-emphasize the role of Lys28 in NAbs-Aβ recognition. Despite the 
representation of specific (dimeric) conformations, lack of Lys28 drastically 
diminishes the NAbs-Aβ binding. The revival of NAbs-Aβ binding upon the inclusion 
of Lys28 once again supports its role in NAbs-Aβ to Aβ interaction (Figure 27). 
Comparison of the promising NAbs-Aβ binding candidates among 24 peptides to wt 
Aβ1-40 and Aβ1-42 revealed that NAbs-Aβ preferential binds towards peptides 
exhibiting dimeric conformation (Figure 28). In addition, parallel dimers, cyclic 
peptides and truncated 28-40 showed good binding to NAbs-Aβ. This is consistent to 
the previous observation where Cys-Aβ1-40 that has the tendency to form dimers 
(Figure 19-Figure 21) showed improved recognition by NAbs-Aβ (Figure 18). These 
results suggest that the right conformation (parallel, anti-parallel or cyclic) is 
important along with the presence of Lys28 for the NAbs-Aβ to Aβ interaction (Figure 
31).  
 
The same set of peptides probed using C-terminal Aβ1-40 specific and mid-terminal 
specific monoclonal antibodies clearly demonstrates that the antibodies binding was 
not because of any unspecific molecular clouding effect of the conformationally fixed 
peptides (Figure 32).  
 
Finally, these results confirmed the binding of NAbs-Aβ has a preferentially improved 
binding towards anti-parallel flexible dimers. Thus we conclude that the NAbs-Aβ 
binding is specific to certain conformation and sequence of Aβ. Further, we propose 
that affinity purification carried out in our laboratories using N-terminal cysteine 
tagged Aβ could possibly help in isolation of the oligomer specific NAbs-Aβ 
antibodies from the IVIG preparation. This isolation procedure further helps in 
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selective isolation of oligomer-specific autoantibodies help from IVIG where both 
oligomer specific and fibril specific autoantibodies coexist.  
 
4.4 Comparison of NAbs-Aβ vs Aβ specific monoclonal antibodies 
Taken together, NAbs-Aβ found in the human sera, contain oligomer specific 
antibodies according to the results discussed in the previous chapter and consistent 
with other reports as well as fibril specific antibodies (Britschgi et al., 2009; Dodel et 
al., 2011; O'Nuallain et al., 2008). It is proposed that in the diseased individuals NAbs-
Aβ might be diminished and thereby impairing Aβ clearance, which leads to the 
disease progression (Dodel et al., 2011). When antibodies are considered for the 
immunotherapy, it is very important to target exclusively the toxic oligomers and 
leaving the physiological Aβ undisturbed. The results in this current work clearly 
demonstrates that affinity purified antibodies recognize low-molecular weight 
oligomers of Aβ and does not interact with neither fibril conformation nor the 
monomers that are required for physiological neuronal functions. When compared 
with other antibodies, NAbs-Aβ recognize the dimeric Aβ species (Figure 18), (Figure 
43) and β-sheet enriched trimer and has no interaction with Aβ1-40 and binds to Aβ1-42 
monomers or to the break down products (Figure 15). On the other hand, oligomer 
specific A11 antibodies do recognize low-molecular weight forms of Aβ, here again, 
these may be break down products of the oligomers which were disturbed while 
boiling the samples (Figure 43). Interestingly Aβ1-40;G29,33Ile mutants could display the 
trimeric structure unaffected or reformed despite the boiling step after 
Immunoprecipitation, this implies either the trimeric structure is stable or the mutation 
tend to form trimers in solution form without any incubation steps. The Aβ toxicity is 
supposed to be due to the presence of SDS-stable oligomers. On the contrary, Aβ1-
40;G29,33Ile mutants, despite being SDS-stable are non-toxic in our experiments. 3D6 
antibodies recognize all the species except N-terminal cysteine added Aβ1-40. N-
terminal specific monoclonal antibody 3D6 might not be the best option for 
immunotherapy considering its strong binding ability towards the physiological 
importance of monomeric Aβ and could also bind to the neuroprotective sAPP-α. 
Comparing m266, NAbs-Aβ could stop the fibrillation at its initial stages (Figure 44).  
 
   DISCUSSION 
 
   90 
We hypothesize that NAbs-Aβ were either produced to target oligomeric forms of Aβ 
or the p3 region (24-42) released subsequent to α-secretase cleavage. We also propose 
that the role of NAbs-Aβ is to clear the accumulation of p3, due to aging when the 
NAbs-Aβ are decreased and there might be a switch from α-secretase cleavage (non-
amyloidogenic) to β-secretase cleavage pathway (amyloidogenic). Schematic diagram 
explains comparing the NAbs-Aβ, 3D6 and m266 binding region (Figure 48). 
 
Figure 48 Schematic diagram: of secretase activities and antibody binding domain on Aβ peptides 
 
4.5 Characterization of oligomers of Aβ1-40;G29,33Ile 
Previously, it was shown that NAbs-Aβ recognized a double mutant form of Aβ 
peptide (4.2)(Figure 34), and preferentially improved binding towards oligomers of Aβ 
(4.3). Interestingly, the substitution of isoleucine at Gly29 and Gly33 of Aβ1-40 
instantly triggered the formation of stable low-molecular weight oligomers (Figure 
33). In Aβ1-42 the double substitution of isoleucine at Gly29 and Gly33 forms higher 
aggregates, whereas in Aβ1-40 the aggregation stops after tetramer formation. This 
effect shows the crucial role of those two CTE amino acids in determining the 
aggregation pattern. The importance of GXXXG was reported by Muthaulp et al 
where they claim that the GXXXG domain responsible for APP dimerization (Munter 
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et al., 2007). Further, they could show that replacing Gly29 or Gly33 with alanine or 
isoleucine prevents APP dimerization. On the contrary, our observation proposes 
another hypothesis that the mutations at GXXXG domain break the helical structure 
provided by the glycine residues by substituting with hydrophobic amino acid 
isoleucine. 
 
Toxicity assays confirm that the wild type and the mutant peptides are non-toxic in the 
freshly prepared-monomerized conditions both on neuronal and microglial cell lines 
(Figure 35-Figure 38). Several reports claim that the anti-inflammatory agents help to 
fight against AD (McGeer et al., 1990). In this toxicity experiment, the treatment of an 
anti-inflammatory drug CNI-1493 helped the cell survival against the Aβ induced 
toxicity.  
 
In line with the previous studies from our laboratory (Bach et al.) and Kayed’s report 
of oligomerization of wt Aβ1-40 and Aβ1-42 using their protocol (Kayed et al., 2003), we 
induced a toxic effect on both used cell lines and treatment of CNI-1493 could 
improve the cell survival (Figure 39), (Figure 41). Surprisingly, the double mutants 
Aβ1-40;G29,33Ile and Aβ1-42;G29,33Ile showed no observable toxic effect on the cells in the 
same oligomerization conditions (Figure 40) (Figure 42). These data indicates that the 
mutants Aβ1-40;G29,33Ile and Aβ1-42;G29,33Ile follow a different oligomerization pattern and 
does not induce cell toxicity in these oligomerization conditions. One possible 
explanation for this lack of toxicity is that the aggregation rate and growth of 
oligomers are more crucial to exert Aβ toxicity than a stable oligomeric form of Aβ 
(Jan et al.). These results also demonstrate that the CNI-1493 specifically binds to 
toxic conformation of the peptide. The effect of CNI-1493 on Aβ oligomers will be 
dealt in details in the following chapter (4.6).  
4.6 Effect of an anti-inflammatory drug CNI-1493 on Aβ oligomers 
Anti-inflammatory drug CNI-1493 could reduce the plaque burden and improve 
cognition in APP over-expressing transgenic mice model (Bacher et al., 2008). CNI-
1493 that is already in clinical phase II research for Corn’s disease has MAP-kinase 
inhibitory action. Previous studies in our laboratory demonstrated that CNI-1493 
decreases the plaque deposition and improves cognition in transgenic animals 
mimicking Alzheimer’s disease.  
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Previously the protective effect of CNI-1493 was shown to rescue cells from Aβ 
induced cytotoxicity (Figure 39). In this study, CNI-1493 showed a destabilizing 
effect on the toxic oligomeric conformation of Aβ peptide. Western blotting results 
supports this proposal as the Aβ oligomers electrophoresed in the presence of CNI-
1493 could break the SDS-stable oligomers and increase the monomers and low-
molecular weight Aβ (Figure 45). A11 antibodies were raised against conformational 
epitope of Aβ (Kayed et al., 2003). Dot blotting with oligomer specific A11 antibodies 
showed that the toxic conformation of the peptide is lost in a concentration dependent 
manner (Figure 46). These data suggest that CNI-1493 might also be effective, not 
only with its anti-inflammatory nature but also, against Aβ oligomers and its toxic 
conformation. 
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4.7 FUTURE PERSPECTIVES 
In this thesis, the characterization of the crucial Aβ epitope of naturally occurring 
autoantibodies, characterization of a novel Aβ oligomer, and effects of a non-steroidal 
anti-inflammatory drug on crucial players of AD were investigated. It was shown that 
naturally occurring autoantibodies contain antibodies against a specific conformational 
Aβ epitope. Despite the enormous amount of efforts taken by scientific communities 
both in academia and bio-pharmaceutical industries, there are very few drug 
candidates entering clinical phases. Recently, there are some dropouts from clinical 
phase III trials due to adverse effects. Alarmingly, at this point of time there is an 
urgent need for drugs that are efficient and safe to use. In this context, the naturally 
occurring conformation specific autoantibodies could be of great help to develop a 
future antibody treatment for AD.  Although, the IVIG immunotherapy for AD has 
successfully entered the confirmatory phase of the clinical phase III, considering the 
number of AD patients and cost involved in the IVIG preparations it is very important 
to look for alternatives approaches. Considering these aspects, deriving monoclonal 
antibodies using reverse translational approaches from the conformational 
autoantibodies against Aβ might be a promising approach that could be cost effective 
and very efficient. Among the compared Aβ species, Aβ double mutant trimers show 
highest binding towards NAbs-Aβ and thus might become a promising candidate for 
active vaccination for AD that might raise conformation specific antibodies in healthy 
individuals to protect them from AD risk. In addition, the Aβ1-40;G29,33Ile trimers could 
also be used for identifying the B-cells that contain the natural antibodies against 
oligomeric Aβ and thereby useful to produce monoclonal antibodies for 
immunotherapy approaches.  The high affinity of NAbs-Aβ towards Aβ1-40;G29,33Ile 
trimers could also be exploited to develop an assay to measure oligomer specific 
autoantibodies present in the human sera. This assay will therefore be useful to 
speculate the subjects having low oligomer specific antibodies having more chance of 
developing AD and additionally, this assay could also be used to monitor the 
improvement among subjects receiving Aβ active immunotherapy for AD clinical 
trials. Neuroinflammation has been reported to be involved in the progression of AD. 
CNI-1493, a non-steroidal anti-inflammatory was shown to be effectively against toxic 
Aβ oligomers that are closely associated with AD. Thus, CNI-1493, which is currently 
in the clinical trial phase II for Corhn’s disease could be effective against AD as well.  
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5 SUMMARY 
SUMMARY 
The broad objective of this study is to unravel the potential effect of naturally 
occurring autoantibodies (NAbs) and CNI-1493 (immunomodulatory compound) on 
Amyloid beta peptide (Aβ) oligomers. Extracellular accumulation of Aβ peptide in the 
brain is suspected to cause and trigger the progression of Alzheimer’s disease (AD). 
The exact physiological role of Aβ remains unclear. The oligomeric forms Aβ impair 
synaptic activity. Hence, immunotherapeutic approach targeting Aβ is one of the 
promising strategies to treat AD. One of the challenges in the immunotherapy 
approach is to specifically target the toxic misfolded forms of Aβ without disturbing 
the physiological levels of Aβ monomers. Naturally occurring autoantibodies against 
Aβ are reduced in AD patients. 
 
In the first chapter, I have characterized the Aβ epitope region of Aβ specific-naturally 
occurring autoantibodies (NAbs-Aβ) using binding studies. I compared the binding 
ability of NAbs-Aβ towards a variety of mutated and truncated Aβ peptides. NAbs-Aβ 
had greater binding ability towards the C-terminal sequence of Aβ, which is 
membrane bound. The C-terminal end of Aβ is crucial for the formation of Aβ 
oligomerization. Hence, C-terminal specificity of NAbs-Aβ could help in the 
minimizing of Aβ oligomerization. Additionally, this specificity also rules out the 
possible interactions of NAbs-Aβ with membrane bound amyloid precursor protein 
(APP), Aβ monomers and fibrils. Further studies on Aβ epitope characterization of 
NAbs-Aβ were performed using site-directed mutagenesis. The results indicated that 
the lysine at 28th and isoleucine at 32nd position of Aβ are crucial for the binding of 
NAbs-Aβ. Deletion or substitution of any of these two amino acids at their respective 
positions lead to loss of binding. Additional binding studies using conformationally 
fixed ‘click’ Aβ peptides indicated that the NAbs-Aβ are specific for low-molecular 
weight anti-parallel dimers. Interestingly, NAbs-Aβ showed excellent binding towards 
Aβ with two substitution mutations at C-terminal (Aβ1-40;G29,33Ile) end. In the second 
chapter, characterization of Aβ1-40;G29,33Ile showed that the peptide undergo a different 
oligomerization process to form SDS-stable trimers. Cytotoxicity studies showed that 
Aβ wild type forms toxic oligomers at certain incubation conditions where as Aβ1-
40;G29,33Ile remains non-toxic under the same conditions. In-line with the results, 
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according to my current understanding, Aβ1-40;G29,33Ile is the first oligomeric Aβ species 
that is stable and has high affinity to NAbs-Aβ.  
 
Non-steroidal anti-inflammatory drugs are reported to provide beneficial effects in 
AD. In the third chapter, I have investigated the role of CNI-1493, which is an anti-
inflammatory drug. In vitro studies show that CNI-1493 binds to Aβ oligomers and 
destabilizes the complex to monomers.  
 
In this study, I have characterized in detail, the effect of two immune system related 
AD drug candidates, NAbs-Aβ and CNI-1493, on Aβ oligomers. These findings help 
our understanding about the NAbs-Aβ and support their potential role as a safe and 
efficient AD immunotherapy candidates. The immunomodulatory effect combined 
with its role on Aβ oligomers make CNI-1493 an interesting drug candidate for AD 
therapeutic studies. In addition, the novel Aβ oligomer could be developed as a 
potential vaccine and diagnostic tool for NAbs-Aβ after further characterization. 
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6 ZUSAMMENFASSUNG 
Das umfassende Ziel dieser Arbeit ist es die Effekte von natürlich vorkommenden 
Autoantikörpern (Nabs) und CNI-1493 (immunmodulatorische Substanz) auf 
Amyloid-beta (Aβ) Oligomere zu beschreiben. Die extrazelluläre Anreicherung von 
Aβ im Gehirn steht im Verdacht Ursache und Auslöser der Alzheimer’schen Demenz 
(AD) zu sein. Die genaue physiologische Rolle von Aβ ist jedoch unklar. Jüngere 
Ergebnisse zeigen dass monomeres Aβ an der normalern synaptischen Aktivität 
beteiligt sein könnte. Im Gegensatz dazu behindert oligomeres Aβ die synaptische 
Aktivität. Daher ist ein immuntherapeutischer Ansatz, der Aβ zum Ziel hat, eine 
vielversprechende Behandlungsstrategie für AD. Eine der Herausforderungen eines 
immuntherapeutischen Ansatzes ist es spezifisch die toxischen, fehl-gefalteten Formen 
von Aβ zu bekämpfen ohne die physiologisch relevanten Aβ Monomere zu stören. Die 
Menge an natürlich vorkommenden Autoantikörpern gegen Aβ ist in AD Patienten 
erniedrigt. 
Im ersten Kapitel habe ich die Aß-Epitop-Region von natürlich vorkommenden Aβ-
Autonatikörpern (Nabs-Aβ) mit Bindungsstudien ermittelt. Ich verglich die Bindung 
von Nabs-Aβ gegenüber einer Reihe von mutierten und verkürzten Aβ-Peptiden. Die 
Nabs–Aβ zeigten eine stärkere Bindung zum C-terminalen Ende von Aβ, das 
membrangebunden vorliegt. Das C-terminale Ende von Aβ ist entscheidend für die 
Oligomerisation. Deshalb könnten C-terminal-spezifische Nabs-Aβ helfen die 
Oligomerisierung zu minimieren. Zusätzlich könnte diese Spezifität eine Interaktion 
von nabs-Aβ mit membrangebundenen Amyloid-Vorläufer-Protein (APP), Aβ-
Monomeren, und Aβ-Fibrillen ausschließen. Weitere Studien zur Epitop-
Charakterisierung wurden mit ortsgerichteter Mutagenese durchgeführt. Die 
Ergebnisse zeigten dass Lysin an Position 28 und Isoleuzin an Position 32 von Aβ 
entscheidend für die Bindung von Nabs-Aß sind. Das Fehlen oder Ersetzen einer 
dieser beiden Aminosäuren führte zum Bindungsverlust. Zusätzliche Bindunsgstudien 
mit konformatorisch fixierten sogenannte Aβ-click-Peptiden zeigten dass nabs-Aβ 
spezifisch für niedermolekulare anti-parallele Aβ Dimere sind. Interessanterweise 
zeigten Nabs-Aβ eine exzellente Bindung mit Aβ mit 2 Muationen am C-terminalen 
Ende (Aβ1-40; G29,33 Ile). Die Charaktersisierung von Aβ1-40; G29,33 Ile zeigte, dass das 
Molekül einen unterschiedlichen Oligomerisierungsprozess durchläuft und SDS-
stabile Trimere bildet. Zytotoxizitäts-Studien zeigten dass Aβ-Wildtyp unter 
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bestimmten Inkubationsbedingungen toxische Oligomere bildet, während Aβ1-40; G29,33 
Ile unter diesen Bedingungen nicht toxisch ist. Entsprechend meines derzeitigen 
Kenntnisstands ist Aβ1-40; G29,33 Ile die erste Aβ-Oligomer-Spezies die stabil ist und eine 
hohe Affinität zu Nabs-Aβ besitzt. 
Nicht-steroidale ani-inflammatorische Heilmittel haben Berichten zufolge einen 
positiven Behandlungs-Effekt bei AD. Ich untersuchte in dieser Arbeit die Rolle von 
CNI-1493, einer anti-inflammatorischen Verbindung. Die in vitro Experimente zeigten 
dass CNI-1493 Aß-Oligomere bindet und den Komplex in Richtung Monomere 
verschiebt.  
 
In dieser Arbeit habe ich im Detail die Effekte von zwei AD-Heilmittel-Kandidaten 
untersucht, die mit dem Immunsystem assoziiert sind; Nabs-Aβ und CNI-1493. Die 
Ergebnisse helfen unserem Verständnis über Nabs-Aβ und unterstützen ihre mögliche 
Rolle als sicheren und effektiven AD-Immuntherapie-Kandidaten. 
Der immunmodulatorische Wirkung von CNI-1493, sowie seine Effekte auf Aβ-
Oligomerbildung machen dieses Molekül zu einem interessanten Arzeinmittel 
Kandidaten für AD Therapie-Studien. Zusätzlich könnte die neue Aβ-Mutante, nach 
weiterer Charakterisierung, als mögliche Vakzine oder diagnostisches Verfahren 
entwickelt werden. 
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8 APPENDIX 
8.1 Abbreviations 
Aa Amino acids 
Aβ Amyloid beta 
AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
AICD APP intracellular domain 
APLP APP like protein 
APP Αmyloid precursor protein 
BACE β-site APP-cleaving enzyme 
BSA Bovine serum albumin 
APPCTF APP C-terminal fragment 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulphoxide 
DTT 1,4 Dithiothreitol 
EDTA Ethylene diamine tetra acetic acid 
ELISA Enzyme linked immunosorbant assay 
FAD Familial Alzheimer’s Disease 
Fig. Figure 
IL Interleukin 
IP Immunoprecipitation 
IVIG Intravenous immunoglobulin 
kDa Kilo Dalton 
LTP Long term potentiation 
MS Mass spectromertry 
M.Wt Molecular weight 
NAbs Naturally occurring autoantibodies 
NAbs-Aβ Affinity purified Aβ specific-NAbs 
NICD Notch intracellular domain 
NTF N-terminal fragment 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
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rpm Revolutions per minute 
sAPPα Soluble APP alpha 
sAPPβ Soluble APP beta 
SDS Sodium dodecyl sulphate 
TBS Tris buffered saline 
TRIS Tris-(hydroxymethyl)-aminomethane 
TNF-α Tumor necrosis factor-α 
wt Wild type 
 
Single letter codes were used for amino acid designation. 
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